

Bijlage Zoekverantwoording

Onderzoeksvraag 1: Voedingsinterventies

Onderzoeksvraag

Wat is het effect van voedingsinterventies (voedingsadviezen, drinkvoeding, sondevoeding, parenterale voeding) op gewichtsverlies en kwaliteit van leven bij patiënten met kanker, hartfalen, COPD en ALS?

| | |
|--------------------------|--|
| Patients/Patiënten | Patiënten met gevorderde kanker, hartfalen, ALS of COPD, en anorexie / gewichtsverlies |
| Intervention/Interventie | Voedingsinterventies (voedingsadviezen, drinkvoeding, sondevoeding, parenterale voeding) |
| Comparison/Vergelijking | Andere voedingsinterventies, geen voedingsinterventie |
| Outcome(s)/Uitkomst(en) | Cruciaal: gewichtsverlies / gewicht, anorexie / eetlust Belangrijk: bijwerkingen, voedsel / calorie inname, lean body mass, kwaliteit van leven, performance status, overleving |

Zoekstrategie

Ovid MEDLINE(R) <1946 to April 09, 2025>

- 1 exp Neoplasms/ (4094844)
- 2 Neoplasm Staging/ (200746)
- 3 cancer\$.ti,ab. (2068768)
- 4 tumor\$.ti,ab. (1617010)
- 5 tumour\$.ti,ab. (289392)
- 6 carcinoma\$.ti,ab. (702367)
- 7 neoplasm\$.ti,ab. (144144)
- 8 lymphoma.ti,ab. (171729)
- 9 melanoma.ti,ab. (124187)
- 10 staging.ti,ab. (87308)
- 11 metastas\$.ti,ab. (398158)
- 12 metastatic.ti,ab. (252282)
- 13 exp Neoplasm Metastasis/ (229716)
- 14 exp neoplastic processes/ (539522)
- 15 neoplastic process\$.ti,ab. (3009)
- 16 non small cell.ti,ab. (74025)
- 17 adenocarcinoma\$.ti,ab. (162139)
- 18 squamous cell.ti,ab. (119224)
- 19 nsclc.ti,ab. (52296)
- 20 osteosarcoma\$.ti,ab. (25925)
- 21 phyllodes.ti,ab. (2076)
- 22 cystosarcoma\$.ti,ab. (569)
- 23 fibroadenoma\$.ti,ab. (3737)
- 24 (non adj small adj cell).ti,ab. (74025)
- 25 (non adj2 small adj2 cell).ti,ab. (74277)
- 26 (nonsmall adj2 cell).ti,ab. (3406)
- 27 plasmacytoma\$.ti,ab. (6444)
- 28 myeloma.ti,ab. (57037)
- 29 multiple myeloma.ti,ab. (42142)
- 30 lymphoblastoma\$.ti,ab. (346)
- 31 lymphocytoma\$.ti,ab. (343)
- 32 lymphosarcoma\$.ti,ab. (4086)
- 33 immunocytoma.ti,ab. (404)
- 34 sarcoma\$.ti,ab. (99835)

35 hodgkin\$.ti,ab. (66674)
36 (nonhodgkin\$ or non hodgkin\$).ti,ab. (38631)
37 malignan\$.ti,ab. (626334)
38 or/1-37 (4882127)
39 exp Heart Failure/ (159248)
40 (heart adj2 failure*).tw. (199178)
41 (cardiac adj2 failure*).tw. (15605)
42 (myocardial adj2 failure*).tw. (3651)
43 (heart adj2 decompensat*).tw. (4898)
44 heart failure.tw. (198376)
45 cardiac failure.tw. (11995)
46 or/39-45 (252123)
47 Lung Diseases, Obstructive/ (18314)
48 exp Pulmonary Disease, Chronic Obstructive/ (71988)
49 emphysema\$.mp. (37445)
50 (chronic\$ adj3 bronchiti\$).mp. (11686)
51 (obstruct\$ adj3 (pulmonary or lung\$ or airway\$ or airflow\$ or bronch\$ or respirat\$)).mp. (133488)
52 COPD.mp. (55595)
53 COAD.mp. (914)
54 COBD.mp. (22)
55 AECB.mp. (218)
56 or/47-55 (174533)
57 exp Amyotrophic Lateral Sclerosis/ (25480)
58 ALS.ti,ab. (43201)
59 Motor Neuron Disease/ (4977)
60 "Charcot disease".ti,ab. (24)
61 "Lou Gehrig".ti,ab. (25)
62 or/57-61 (54183)
63 38 or 46 or 56 or 62 (5311517)
64 Anorexia/ (5602)
65 Weight Loss/ (47184)
66 anorexi*.ti,ab. (35579)
67 (cachex* or cachect*).ti,ab. (9938)
68 (malnourish* or malnutrition or emaciation or "weight loss" or underweight or wasting or wasted or appetite
or starvation).ti,ab. (235521)
69 Cachexia/ (6779)
70 Appetite/ (9158)
71 or/64-70 (285045)
72 63 and 71 (54319)
73 exp Gastrostomy/ (9176)
74 exp Nutrition Therapy/ (119242)
75 exp Intubation, Gastrointestinal/ (10479)
76 exp Jejunostomy/ (3060)
77 (gastrostom* or jejunostom* or ((parenteral or enteral or enteric) adj2 (nutrition or feed*)) or peg or rig or
ppeg or ((feed* or nasogastric) adj2 tube) or ((digestive or gastrointestinal) adj2 intubation)).ti,ab. (101786)
78 exp Dietary Proteins/ (111354)
79 exp Dietary Supplements/ (113078)
80 exp Dietetics/ (8439)
81 Diet/ (199417)
82 Diet, High-Protein/ (446)
83 Energy Intake/ (46362)
84 exp Energy Drinks/ (1066)
85 exp Carbonated Beverages/ (3428)

86 exp Sugar-Sweetened Beverages/ (1242)
 87 (energ* or diet* or nutrit* or food* or eat*).ti,ab. (1846089)
 88 or/73-87 (2101675)
 89 72 and 88 (15280)
 90 limit 89 to yr="2012 -Current" (8923)
 91 randomized controlled trial.pt. (635062)
 92 controlled clinical trial.pt. (95668)
 93 randomized.ab. (586921)
 94 placebo.ab. (232304)
 95 clinical trials as topic.sh. (204747)
 96 randomly.ab. (378907)
 97 trial.ti. (284868)
 98 91 or 92 or 93 or 94 or 95 or 96 or 97 (1478663)
 99 exp animals/ not humans.sh. (5325645)
 100 98 not 99 (1348079)
 101 meta-analysis.mp,pt. or review.pt. or search:.tw. (3507404)
 102 100 or 101 (4616550)
 103 90 and 102 (3083)

Ovid MEDLINE(R) Epub Ahead of Print <April 09, 2025>

Ovid MEDLINE(R) Daily Update <April 09, 2025>

1 exp Neoplasms/ (2351)
 2 Neoplasm Staging/ (89)
 3 cancer\$.ti,ab. (30196)
 4 tumor\$.ti,ab. (18148)
 5 tumour\$.ti,ab. (2255)
 6 carcinoma\$.ti,ab. (6874)
 7 neoplasm\$.ti,ab. (1831)
 8 lymphoma.ti,ab. (1861)
 9 melanoma.ti,ab. (1377)
 10 staging.ti,ab. (1278)
 11 metastas\$.ti,ab. (4827)
 12 metastatic.ti,ab. (3189)
 13 exp Neoplasm Metastasis/ (110)
 14 exp neoplastic processes/ (233)
 15 neoplastic process\$.ti,ab. (24)
 16 non small cell.ti,ab. (1186)
 17 adenocarcinoma\$.ti,ab. (1848)
 18 squamous cell.ti,ab. (1564)
 19 nsclc.ti,ab. (866)
 20 osteosarcoma\$.ti,ab. (247)
 21 phyllodes.ti,ab. (17)
 22 cystosarcoma\$.ti,ab. (2)
 23 fibroadenoma\$.ti,ab. (78)
 24 (non adj small adj cell).ti,ab. (1186)
 25 (non adj2 small adj2 cell).ti,ab. (1187)
 26 (nonsmall adj2 cell).ti,ab. (45)
 27 plasmacytoma\$.ti,ab. (36)
 28 myeloma.ti,ab. (599)
 29 multiple myeloma.ti,ab. (537)
 30 lymphoblastoma\$.ti,ab. (0)
 31 lymphocytoma\$.ti,ab. (5)
 32 lymphosarcoma\$.ti,ab. (2)

33 immunocytoma.ti,ab. (1)
34 sarcoma\$.ti,ab. (907)
35 hodgkin\$.ti,ab. (478)
36 (nonhodgkin\$ or non hodgkin\$).ti,ab. (289)
37 malignan\$.ti,ab. (7430)
38 or/1-37 (47267)
39 exp Heart Failure/ (88)
40 (heart adj2 failure*).tw. (3333)
41 (cardiac adj2 failure*).tw. (140)
42 (myocardial adj2 failure*).tw. (56)
43 (heart adj2 decompensat*).tw. (87)
44 heart failure.tw. (3328)
45 cardiac failure.tw. (81)
46 or/39-45 (3429)
47 Lung Diseases, Obstructive/ (0)
48 exp Pulmonary Disease, Chronic Obstructive/ (42)
49 emphysema\$.mp. (267)
50 (chronic\$ adj3 bronchiti\$).mp. (61)
51 (obstruct\$ adj3 (pulmonary or lung\$ or airway\$ or airflow\$ or bronch\$ or respirat\$)).mp. (1283)
52 COPD.mp. (864)
53 COAD.mp. (25)
54 COBD.mp. (0)
55 AECB.mp. (0)
56 or/47-55 (1723)
57 exp Amyotrophic Lateral Sclerosis/ (18)
58 ALS.ti,ab. (1144)
59 Motor Neuron Disease/ (3)
60 "Charcot disease".ti,ab. (0)
61 "Lou Gehrig".ti,ab. (0)
62 or/57-61 (1146)
63 38 or 46 or 56 or 62 (52852)
64 Anorexia/ (3)
65 Weight Loss/ (64)
66 anorexi*.ti,ab. (391)
67 (cachex* or cachect*).ti,ab. (109)
68 (malnourish* or malnutrition or emaciation or "weight loss" or underweight or wasting or wasted or appetite
or starvation).ti,ab. (3430)
69 Cachexia/ (2)
70 Appetite/ (2)
71 or/64-70 (3769)
72 63 and 71 (695)
73 exp Gastrostomy/ (2)
74 exp Nutrition Therapy/ (49)
75 exp Intubation, Gastrointestinal/ (2)
76 exp Jejunostomy/ (2)
77 (gastrostom* or jejunostom* or ((parenteral or enteral or enteric) adj2 (nutrition or feed*)) or peg or rig or
pppeg or ((feed* or nasogastric) adj2 tube) or ((digestive or gastrointestinal) adj2 intubation)).ti,ab. (1363)
78 exp Dietary Proteins/ (42)
79 exp Dietary Supplements/ (96)
80 exp Dietetics/ (1)
81 Diet/ (87)
82 Diet, High-Protein/ (0)
83 Energy Intake/ (11)

84 exp Energy Drinks/ (0)
 85 exp Carbonated Beverages/ (0)
 86 exp Sugar-Sweetened Beverages/ (3)
 87 (energ* or diet* or nutrit* or food* or eat*).ti,ab. (32248)
 88 or/73-87 (33111)
 89 72 and 88 (232)
 90 limit 89 to yr="2012 -Current" (204)
 91 randomized controlled trial.pt. (428)
 92 controlled clinical trial.pt. (2)
 93 randomized.ab. (9876)
 94 placebo.ab. (2429)
 95 clinical trials as topic.sh. (44)
 96 randomly.ab. (4762)
 97 trial.ti. (4871)
 98 91 or 92 or 93 or 94 or 95 or 96 or 97 (16536)
 99 exp animals/ not humans.sh. (1939)
 100 98 not 99 (16461)
 101 meta-analysis.mp,pt. or review.pt. or search:.tw. (58768)
 102 100 or 101 (71021)
 103 90 and 102 (63)

Cochrane Library: 10/4/2025

| | | |
|-----|---|--------|
| #1 | MeSH descriptor: [Neoplasms] explode all trees | 126627 |
| #2 | MeSH descriptor: [Neoplasm Staging] explode all trees | 9902 |
| #3 | cancer*.ti,ab | 192504 |
| #4 | tumor*.ti,ab | 71986 |
| #5 | tumour*.ti,ab | 15585 |
| #6 | carcinoma*.ti,ab | 37639 |
| #7 | neoplasm*.ti,ab | 10071 |
| #8 | lymphoma:ti,ab | 11380 |
| #9 | melanoma:ti,ab | 6375 |
| #10 | staging:ti,ab | 6909 |
| #11 | metastas*.ti,ab | 23292 |
| #12 | metastatic:ti,ab | 36719 |
| #13 | MeSH descriptor: [Neoplasm Metastasis] explode all trees | 7622 |
| #14 | MeSH descriptor: [Neoplastic Processes] explode all trees | 15481 |
| #15 | neoplastic process*.ti,ab | 222 |
| #16 | (non NEAR small NEAR cell):ti,ab | 14755 |
| #17 | adenocarcinoma*.ti,ab | 10710 |
| #18 | (squamous NEAR cell):ti,ab | 9398 |
| #19 | nsclc:ti,ab | 12850 |
| #20 | osteosarcoma*.ti,ab | 508 |
| #21 | phylloides:ti,ab | 6 |
| #22 | cystosarcoma*.ti,ab | 0 |
| #23 | fibroadenoma*.ti,ab | 116 |
| #24 | (non NEAR/2 small NEAR/2 cell):ti,ab | 14729 |
| #25 | (nonsmall NEAR/2 cell):ti,ab | 11738 |
| #26 | plasmacytoma*.ti,ab | 145 |
| #27 | myeloma:ti,ab | 6788 |
| #28 | (multiple NEAR myeloma):ti,ab | 6175 |
| #29 | lymphoblastoma*.ti,ab | 0 |
| #30 | lymphocytoma*.ti,ab | 1 |
| #31 | lymphosarcoma*.ti,ab | 22 |

#32 immunocytooma:ti,ab 17

#33 sarcoma*:ti,ab 2979

#34 hodgkin*:ti,ab 5843

#35 (nonhodgkin* or (non NEAR hodgkin*)):ti,ab 3532

#36 malignan*:ti,ab 32473

#37 {or #1-#36} 298353

#38 MeSH descriptor: [Heart Failure] explode all trees 14728

#39 (heart and failure*):ti,ab 38322

#40 (cardiac and failure*):ti,ab 15872

#41 (myocardial and failure*):ti,ab 9918

#42 (heart and decompensat*):ti,ab 2094

#43 #38 or #39 or #40 or #41 or #42 44320

#44 MeSH descriptor: [Lung Diseases, Obstructive] explode all trees 25209

#45 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] 1 tree(s) exploded 7996

#46 emphysema*:ti,ab 1558

#47 (chronic* NEAR/3 bronchiti*):ti,ab 2015

#48 (obstruct* NEAR/3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)):ti,ab 19220

#49 COPD:ti,ab 19875

#50 COAD:ti,ab 101

#51 COBD:ti,ab 2

#52 AECB:ti,ab 139

#53 #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 44732

#54 MeSH descriptor: [Amyotrophic Lateral Sclerosis] explode all trees 893

#55 ALS:ti,ab 2480

#56 MeSH descriptor: [Motor Neuron Disease] this term only 381

#57 "Charcot disease":ti,ab 2

#58 "Lou Gehrig":ti,ab 10

#59 {or #54-#58} 2663

#60 #37 or #43 or #53 or #59 383729

#61 MeSH descriptor: [Anorexia] explode all trees 530

#62 MeSH descriptor: [Weight Loss] explode all trees 9086

#63 anorexi*:ti,ab 4194

#64 (cachex* or cachect*):ti,ab 970

#65 (malnourish* or malnutrition or emaciation or "weight loss" or underweight or wasting or wasted or appetite or starvation):ti,ab 40192

#66 MeSH descriptor: [Cachexia] explode all trees 415

#67 MeSH descriptor: [Appetite] explode all trees 1932

#68 {or #61-#67} 45715

#69 #60 and #68 8789

#70 MeSH descriptor: [Gastrostomy] explode all trees 254

#71 MeSH descriptor: [Nutrition Therapy] explode all trees 12792

#72 MeSH descriptor: [Intubation, Gastrointestinal] explode all trees 849

#73 MeSH descriptor: [Jejunostomy] explode all trees 102

#74 (gastrostom* or jejunostom* or ((parenteral or enteral or enteric) NEAR/2 (nutrition or feed*)) or peg or rig or ppeg or ((feed* or nasogastric) NEAR/2 tube) or ((digestive or gastrointestinal) NEAR/2 intubation)):ti,ab 18292

#75 MeSH descriptor: [Dietary Proteins] explode all trees 5333

#76 MeSH descriptor: [Dietary Supplements] explode all trees 19459

#77 MeSH descriptor: [Dietetics] explode all trees 129

#78 MeSH descriptor: [Diet] this term only 10455

#79 MeSH descriptor: [Diet, High-Protein] this term only 147

#80 MeSH descriptor: [Energy Intake] this term only 6054

#81 MeSH descriptor: [Energy Drinks] explode all trees 133

#82 MeSH descriptor: [Carbonated Beverages] explode all trees 227
 #83 MeSH descriptor: [Sugar-Sweetened Beverages] explode all trees 126
 #84 (energ* or diet* or nutrit* or food* or eat*):ti,ab 184542
 #85 {or #70-#84} 209128
 #86 #69 and #85 with Cochrane Library publication date Between Jan 2012 and Mar 2025 3140

Embase: 10/4/2025

| | | |
|-----|--|---------|
| #1 | 'neoplasm'/exp | 6596867 |
| #2 | 'cancer staging'/exp | 495857 |
| #3 | cancer*:ti,ab | 3544858 |
| #4 | tumor*:ti,ab | 2638609 |
| #5 | tumour*:ti,ab | 465601 |
| #6 | carcinoma*:ti,ab | 1129592 |
| #7 | neoplasm*:ti,ab | 242363 |
| #8 | lymphoma:ti,ab | 301286 |
| #9 | melanoma:ti,ab | 206477 |
| #10 | staging:ti,ab | 171263 |
| #11 | metastas*:ti,ab | 698673 |
| #12 | metastatic:ti,ab | 493453 |
| #13 | 'metastasis'/exp | 910202 |
| #14 | 'oncogenesis and malignant transformation'/exp | 1386284 |
| #15 | neoplastic AND process*:ti,ab | 21722 |
| #16 | (non NEAR/1 small NEAR/1 cell):ti,ab | 150986 |
| #17 | adenocarcinoma*:ti,ab | 300375 |
| #18 | (squamous NEAR/1 cell):ti,ab | 201172 |
| #19 | nsclc:ti,ab | 125060 |
| #20 | osteosarcoma*:ti,ab | 39979 |
| #21 | phylloides:ti,ab | 3426 |
| #22 | cystosarcoma*:ti,ab | 697 |
| #23 | fibroadenoma*:ti,ab | 6005 |
| #24 | (nonsmall NEAR/2 cell):ti,ab | 127604 |
| #25 | plasmacytoma*:ti,ab | 9524 |
| #26 | myeloma:ti,ab | 111893 |
| #27 | (multiple NEAR/1 myeloma):ti,ab | 89872 |
| #28 | lymphoblastoma*:ti,ab | 356 |
| #29 | lymphocytoma*:ti,ab | 463 |
| #30 | lymphosarcoma*:ti,ab | 4613 |
| #31 | immunocytoma:ti,ab | 472 |
| #32 | sarcoma*:ti,ab | 152170 |
| #33 | hodgkin*:ti,ab | 112995 |
| #34 | nonhodgkin*:ti,ab OR ((non NEAR/1 hodgkin*):ti,ab) | 67939 |
| #35 | malignan*:ti,ab | 1092803 |
| #36 | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 | 7872986 |
| #37 | 'heart failure'/exp | 744731 |
| #38 | (heart NEAR/2 failure*):ab,ti | 396400 |

| | | |
|------|---|---------|
| #39. | (myocardial NEAR/2 failure*):ab,ti | 6318 |
| #40. | (cardiac NEAR/2 failure*):ab,ti | 27148 |
| #41. | (heart NEAR/2 decompensat*):ab,ti | 12495 |
| #42. | #37 OR #38 OR #39 OR #40 OR #41 | 811654 |
| #43. | 'chronic obstructive lung disease'/exp | 201140 |
| #44. | emphysema*:ti,ab | 46254 |
| #45. | (chronic* NEAR/3 bronchiti*):ti,ab | 16883 |
| #46. | (obstruct* NEAR/3 (pulmonary OR lung* OR airway* OR airflow* OR bronch* OR respirat*)):ti,ab | 167109 |
| #47. | copd:ti,ab OR coad:ti,ab OR cobd:ti,ab OR aecb:ti,ab | 123906 |
| #48. | #43 OR #44 OR #45 OR #46 OR #47 | 324114 |
| #49. | 'amyotrophic lateral sclerosis'/exp | 54294 |
| #50. | 'motor neuron disease'/de | 15163 |
| #51. | als:ti,ab | 49654 |
| #52. | 'charcot disease':ti,ab | 49 |
| #53. | 'lou gehrig':ti,ab | 273 |
| #54. | #49 OR #50 OR #51 OR #52 OR #53 | 82963 |
| #55. | #36 OR #42 OR #48 OR #54 | 8904168 |
| #56. | 'anorexia'/exp | 78870 |
| #57. | 'body weight loss'/exp | 264030 |
| #58. | 'cachexia'/exp | 20126 |
| #59. | 'malnutrition'/de | 87361 |
| #60. | 'appetite'/exp | 30669 |
| #61. | anorexi*:ti,ab | 58848 |
| #62. | cachex*:ti,ab OR cachect*:ti,ab | 17899 |
| #63. | malnourish*:ti,ab OR malnutrition:ti,ab OR emaciation:ti,ab OR 'weight loss':ti,ab OR underweight:ti,ab OR wasting:ti,ab OR wasted:ti,ab OR appetite:ti,ab OR starvation:ti,ab | 417250 |
| #64. | #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 | 659110 |
| #65. | 'gastrostomy'/exp | 15602 |
| #66. | 'diet therapy'/de | 75569 |
| #67. | 'diet supplementation'/de | 107984 |
| #68. | 'nutritional support'/de | 25454 |
| #69. | 'digestive tract intubation'/exp | 8381 |
| #70. | 'enterostomy'/de | 2666 |
| #71. | 'jejunostomy'/exp | 7636 |
| #72. | gastrostom*:ti,ab OR jejunostom*:ti,ab OR (((parenteral OR enteral OR enteric) NEAR/2 (nutrition OR feed*)):ti,ab) OR peg:ti,ab OR rig:ti,ab OR ppeg:ti,ab OR (((feed* OR nasogastric) NEAR/2 tube):ti,ab) OR (((digestive OR gastrointestinal) NEAR/2 intubation):ti,ab) | 178591 |
| #73. | 'dietary intake'/de | 105793 |
| #74. | 'nutrition'/de | 138307 |
| #75. | 'dietary supplement'/de | 28884 |
| #76. | 'dietetics'/de | 7957 |
| #77. | 'diet'/de | 285635 |
| #78. | 'protein diet'/de | 8327 |
| #79. | 'caloric intake'/de | 83328 |
| #80. | 'carbonated beverage'/exp | 4088 |
| #81. | 'sweetened beverage'/exp | 5318 |
| #82. | energ*:ti,ab OR diet*:ti,ab OR nutrit*:ti,ab OR food*:ti,ab OR eat*:ti,ab | 2892256 |

| | | |
|------|---|---------|
| #83. | #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 | 3190904 |
| #84. | #55 AND #64 AND #83 | 40214 |
| #85. | #55 AND #64 AND #83 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) AND ([article]/lim OR [article in press]/lim OR [review]/lim) AND ([dutch]/lim OR [english]/lim) AND [embase]/lim AND [2012-2025]/py | 1597 |

Tabel 1. Resultaten van zoekactie van onderzoeksvraag 1

| Database | Aantal |
|--|-------------|
| Medline | 3083 |
| PreMedline | 63 |
| CDSR | 90 |
| CENTRAL | 3099 |
| Embase | 1597 |
| Totaal aantal resultaten | 7932 |
| Aantal geëxcludeerd (dubbelen, foute taal) | 1996 |
| Totaal aantal unieke resultaten | 5936 |

Tabel 2. Overzicht van geëxcludeerde studies gebaseerd op beoordeling van de volledige tekst van onderzoeksvraag 1

| Referentie | Reden voor exclusie |
|---|---|
| Ahmadi A, Eftekhari MH, Mazloom Z et al (2020) Fortified whey beverage for improving muscle mass in chronic obstructive pulmonary disease: a single-blind, randomized clinical trial. <i>Respir Res</i> 21:216 | GOLD II-III |
| Ahnfeldt-Mollerup P, Hey H, Johansen C et al (2015) The effect of protein supplementation on quality of life, physical function, and muscle strength in patients with chronic obstructive pulmonary disease. <i>Eur J Phys Rehabil Med</i> 51:447–456 | Ongeveer 50% had mild to moderate COPD |
| Al-Batran, S.-E., et al. Home parenteral nutrition (HPN) using individually compounded PN administered via multi-chamber Eurotubes versus PN administered via 2/3-chamber bags in patients with metastatic or localized solid tumors requiring HPN: the randomized IKF-010 PEKANNUSS trial of AIO. <i>Journal of clinical oncology</i> , 2023. 41, e24123 DOI: 10.1200/jco.2023.41.16_suppl.e24123. | Abstract |
| Allenby, T.H., et al., A systematic review of home-based dietary interventions during radiation therapy for cancer. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020. 16: p. 10-16. | Geen relevante RCT's |
| Alshadwi, A., et al., Nutritional considerations for head and neck cancer patients: a review of the literature. <i>Journal of Oral & Maxillofacial Surgery</i> , 2013. 71(11): p. 1853-60. | Geen methodologische informatie; narrative review |
| AmenaOmer, S., H. Shyam, and S. Siddiqui Impacts of high protein supplementation on oncology patients. <i>JPEN. Journal of parenteral and enteral nutrition</i> , 2021. 45, S123-s125 DOI: 10.1002/jpen.2095. | Poster |
| Andrade, A.P.D., et al., Major considerations of enteral nutritional therapy in patients with congestive heart failure: a systematic review. <i>International Journal of Nutrology</i> , 2024. 17. | Narrative review, geen kwaliteitsbeoordeling van geïnccludeerde studies |
| Anonymous, Validity of dietary intake methods in cancer cachexia. <i>Current Opinion in Supportive & Palliative Care</i> , 2024. 18(3): p. 292. | Erratum |

| Referentie | Reden voor exclusie |
|---|--|
| Arvia, G., et al., Treatment of cancer cachexia in the very advanced or terminal phase: A systematic review. <i>Italian Journal of Medicine</i> , 2013. 7(4): p. 253-258. | Enkel PubMed, geen voedingsinterventies |
| Bagheri, A., et al., The Effect of Mediterranean Diet on Body Composition, Inflammatory Factors, and Nutritional Status in Patients with Cachexia Induced by Colorectal Cancer: A Randomized Clinical Trial. <i>Integrative Cancer Therapies</i> , 2023. 22: p. 15347354231195322. | Hoofdzakelijk st. III colorectale kanker: niet palliatief |
| Baguley, B.J., et al., A rapid review of nutrition and exercise approaches to managing unintentional weight loss, muscle loss, and malnutrition in cancer. <i>Oncologist</i> , 2024. 07: p. 07. | Narrative review |
| Baguley, B.J., et al., Effectiveness of combined nutrition and exercise interventions on body weight, lean mass, and fat mass in adults diagnosed with cancer: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2023. 81(6): p. 625-646. | Multimodale therapie |
| Baker, J., et al., Quality of life after early enteral feeding versus standard care for proven or suspected advanced epithelial ovarian cancer: Results from a randomised trial. <i>Gynecologic Oncology</i> , 2015. 137(3): p. 516-22. | Postoperatieve voeding |
| Baldwin, C., The effectiveness of nutritional interventions in malnutrition and cachexia. <i>Proceedings of the Nutrition Society</i> , 2015. 74(4): p. 397-404. | Narrative review |
| Balogun, N., et al., Noninvasive nutritional management of ovarian cancer patients: beyond intestinal obstruction. <i>International Journal of Gynecological Cancer</i> , 2012. 22(6): p. 1089-95. | Geen methodologische informatie; narrative review |
| Bille, S.J., et al., The Effect of Special Diets on Weight and Nutritional Intake in Hematological Cancer Patients: A Randomized Study. <i>Nutrition & Cancer</i> , 2018. 70(6): p. 874-878. | Onduidelijk hoeveel patiënten palliatieve chemotherapie kregen |
| Bonilla, P.J., et al. Nutritional intervention in malnourished hospitalized patients with heart failure and hypoalbuminemia: subanalysis of PICNIC study. <i>European journal of heart failure</i> , 2016. 18, 37-38 DOI: 10.1002/ejhf.539. | Poster |
| Bonilla-Palomas, J.L., et al., Does nutritional intervention maintain its prognostic benefit in the long term for malnourished patients hospitalised for heart failure? <i>Revista Clinica Espanola</i> , 2018. 218(2): p. 58-60. | Geen palliatieve populatie |
| Bonilla-Palomas, J.L., et al., Nutritional Intervention in Malnourished Hospitalized Patients with Heart Failure. <i>Archives of Medical Research</i> , 2016. 47(7): p. 535-540. | Geen palliatieve populatie |
| Bouleuc, C., et al. Multicenter randomized controlled trial for advanced cancer patients receiving parenteral nutrition (PN) versus oral feeding (OF): results of AlimK study. <i>Journal of clinical oncology</i> , 2018. 36, DOI: 10.1200/jco.2018.36.15_suppl.10029. | Abstract |
| Bourdel-Marchasson, I., et al. Nutritional advices in older patients at risk for malnutrition during chemotherapy for cancer: no effect on mortality decreased rate of severe infections. Multicentre inogad study. <i>Clinical nutrition, supplement</i> , 2012. 7, 16 DOI: 10.1016/S1744-1161(12)70038-8. | Abstract |
| Bourdel-Marchasson, I., et al. The effects of nutritional advices in older patients at risk for malnutrition during chemotherapy for cancer on the quality of intakes. Multicentre inogad study. <i>Clinical nutrition (Edinburgh, Scotland)</i> , 2013. 32, S64. | Abstract |
| Bourdel-Marchasson, I., et al., Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial. <i>PLoS ONE [Electronic Resource]</i> , 2014. 9(9): p. e108687. | "Patients at risk of malnutrition": dus nog geen malnutritie |
| Calder, P., et al. Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease (COPD): a randomized, double-blind controlled trial. <i>Journal of cachexia, sarcopenia and muscle</i> , 2017. 8, 174 DOI: 10.1002/jcsm.12182. | Abstract |

| Referentie | Reden voor exclusie |
|--|---|
| Calder, P.C., et al., Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018. 9(1): p. 28-40. | Onduidelijk hoeveel palliatieve patiënten |
| Camere, M., et al. An oral nutritional supplement reduces malnutrition in chronic obstructive pulmonary disease patients. <i>Clinical nutrition (Edinburgh, Scotland)</i> , 2016. 35, S187-s188. | Abstract |
| Cano-Torres EA, Simental-Mendía LE, Morales-Garza LA, Ramos-Delgado JM, Reyes-Gonzalez MM, Sánchez-Nava VM, et al. Impact of nutritional intervention on length of hospital stay and mortality among hospitalized patients with malnutrition: a clinical randomized controlled trial. <i>Journal of American College of Nutrition</i> 2017;36(4):235-9 | Mix van aandoeningen |
| Capitao, C., et al., Protein intake and muscle mass maintenance in patients with cancer types with high prevalence of sarcopenia: a systematic review. <i>Supportive Care in Cancer</i> , 2022. 30(4): p. 3007-3015. | Tijdens kankerbehandeling |
| Capozzi, L.C.; McNeely, M.L.; Lau, H.Y.; Reimer, R.A.; Giese-Davis, J.; Fung, T.S.; Culos-Reed, S.N. Patient-reported outcomes, body composition, and nutrition status in patients with head and neck cancer: Results from an exploratory randomized controlled exercise trial. <i>Cancer</i> 2016, 122, 1185–1200 | Is eigenlijk een lifestyle interventie: de voedingsinterventie is niet af te lijnen |
| Caulfield C. Examining the benefits of an oral nutritional supplement (ONS) with regard to its safety, tolerance and clinical efficacy in improving nutritional status of undernourished, hospitalised patients. <i>Clinical Nutrition, Supplement</i> 2012;7(1):280 | Abstract |
| Chang, C., et al., Clinical practice guidelines for the nutrition of colorectal cancer patients: a systematic review. <i>Supportive Care in Cancer</i> , 2024. 32(3). | Review van richtlijnen |
| Chen, Y.-Y., et al. Efficacy of different nutritional intervention on nutritional status and quality of life for local advanced nasopharyngeal carcinoma patients: a prospective clinical trial. <i>Annals of oncology</i> , 2019. 30, v464 DOI: 10.1093/annonc/mdz252.036. | Abstract |
| Childs DS, Jatoi A (2019) A hunger for hunger: a review of palliative therapies for cancer-associated anorexia. <i>Ann Palliat Med</i> 8(1):50–58 | Narrative review |
| Cho, K.H., et al., Effects of protein-enriched nutritional support on skeletal muscle mass and rehabilitative outcomes in brain tumor patients: a randomized controlled trial. <i>Scientific Reports</i> , 2024. 14(1): p. 12909. | Gemengde populatie |
| Chow, R., et al., Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. <i>Supportive Care in Cancer</i> , 2020. 28(3): p. 979-1010. | Focus op ongewenste effecten |
| Chow, R., et al., Enteral and parenteral nutrition in patients with cancer: complication rates compared—updated systematic review and meta-analysis. <i>BMJ supportive & palliative care</i> , 2025. 31: p. 31. | Focus op ongewenste effecten |
| Clemente-Suarez, V.J., et al., Nutritional and Exercise Interventions in Cancer-Related Cachexia: An Extensive Narrative Review. <i>International Journal of Environmental Research & Public Health</i> [Electronic Resource], 2022. 19(8): p. 11. | Narrative review |
| Colatruglio, S., et al. Nutrition support in gastrointestinal cancer patients: a randomized clinical trial. <i>Clinical nutrition, supplement</i> , 2012. 7, 74 DOI: 10.1016/S1744-1161(12)70174-6. | Abstract |
| Collins, P., R. Stratton, and M. Elia Nutritional support in chronic obstructive pulmonary disease (COPD): a randomised trial. <i>Clinical nutrition (Edinburgh, Scotland)</i> , 2014. 33, S65. | Abstract |
| Collins, P.F., M. Elia, and R.J. Stratton, Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Respirology</i> , 2013. 18(4): p. 616-29. | Stabiele COPD |

| Referentie | Reden voor exclusie |
|---|---|
| Collins, P.F., R.J. Stratton, and M. Elia, Nutritional support in chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2012. 95(6): p. 1385-95. | Stabiele COPD |
| Cooper, C., et al., Understanding and managing cancer-related weight loss and anorexia: Insights from a systematic review of qualitative research. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015. 6(1): p. 99-111. | Kwalitatief onderzoek |
| Correia Filho, R.C., et al., Nutrological and pharmacological approaches to cancer cachexia: a systematic review. <i>International Journal of Nutrology</i> , 2024. 17(1). | Geen overzicht en kwaliteitsbeoordeling van geïnccludeerde studies |
| de Bisschop C, Caron F, Ingrand P et al (2021) Does branched-chain amino acid supplementation improve pulmonary rehabilitation effect in COPD? <i>Respir Med</i> 189:106642 | Stabiele COPD; foute interventie |
| de Jorge-Huerta, L., et al., A Narrative Review of the Diagnosis and Treatment of Sarcopenia and Malnutrition in Patients with Heart Failure. <i>Nutrients</i> , 2024. 16(16): p. 15. | Narrative review |
| de Lacerda, L.L.M., et al., Enteral nutrition and congestive heart failure: a systematic review. <i>International Journal of Nutrology</i> , 2023. 16(2). | Geen overzicht en kwaliteitsbeoordeling van geïnccludeerde studies |
| De Marchi, F., et al., A Telehealth Intervention for Nutritional Counseling in Amyotrophic Lateral Sclerosis Patients. <i>Journal of Clinical Medicine</i> , 2022. 11(15). | Geen RCT |
| De Waele, E., et al., Nutrition therapy in cachectic cancer patients. The Tight Caloric Control (TiCaCo) pilot trial. <i>Appetite</i> , 2015. 91: p. 298-301. | 80% met st. III-IV kanker |
| De, W.E., et al. Nutrition therapy promotes overall survival in cachectic cancer patients through a biophysical pathway: the ticaconco trial. <i>Clinical nutrition ESPEN</i> , 2021. 46, S715 DOI: 10.1016/j.clnesp.2021.09.484. | Abstract |
| Degirmenci, D., H. Sahin, and M. Soylu The effect of enteral nutrition support on muscle function capacity and pulmonary functions in malnourished patients with Chronic Obstructive Pulmonary Disease. <i>Progress in nutrition</i> , 2018. 20, 120-127 DOI: 10.23751/pn.v20i1.6043. | Onduidelijk hoeveel patiënten met gevorderde COPD; foute uitkomsten |
| Deutz NE, Ziegler TR, Matheson EM et al (2021) Reduced mortality risk in malnourished hospitalized older adult patients with COPD treated with a specialized oral nutritional supplement: Subgroup analysis of the NOURISH study. <i>Clin Nutr</i> 40:1388–1395 | Voedingssupplement |
| Deutz, N., et al. A randomized placebo-controlled clinical trial of readmission and mortality in malnourished older hospitalized adults treated with a specialized oral nutrition supplement. <i>JPEN. Journal of parenteral and enteral nutrition</i> , 2016. 40, 127-128 DOI: 10.1177/0148607115621052. | Abstract |
| Deutz, N., et al. Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement: a randomized clinical trial. <i>Clinical nutrition (Edinburgh, Scotland)</i> , 2016. 35, 18-26 DOI: 10.1016/j.clnu.2015.12.010. | Dubbel |
| Deutz, N.E., et al., Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement: A randomized clinical trial. <i>Clinical Nutrition</i> , 2016. 35(1): p. 18-26. | 40% geen populatie beantwoordend aan PICO; minderheid aan palliatieve patiënten |
| Dingemans, A.M., et al., High Protein Oral Nutritional Supplements Enable the Majority of Cancer Patients to Meet Protein Intake Recommendations during Systemic Anti-Cancer Treatment: A Randomised Controlled Parallel-Group Study. <i>Nutrients</i> , 2023. 15(24). | Geen palliatieve behandeling |

| Referentie | Reden voor exclusie |
|---|---|
| Dintinjana, R., et al. Effects of nutritional support in patients with colorectal cancer. Journal of cachexia, sarcopenia and muscle, 2012. 3, 68 DOI: 10.1007/s13539-012-0056-8. | Abstract |
| Essat, M., et al., Understanding the current nutritional management for people with amyotrophic lateral sclerosis - A mapping review. Clinical Nutrition ESPEN, 2022. 49: p. 328-340. | Geen RCT's |
| Faber, J., et al., Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. Journal of Cachexia, Sarcopenia and Muscle, 2015: p. 32-44. | >50% met st. I-III |
| Feinberg, J., et al., Nutrition support in hospitalised adults at nutritional risk. Cochrane Database of Systematic Reviews, 2017. 2017(5). | Niet gerapporteerd volgens de aandoeeningen in de PICO |
| Fekete, M., et al., The Effectiveness of Supplementation with Key Vitamins, Minerals, Antioxidants and Specific Nutritional Supplements in COPD-A Review. Nutrients, 2023. 15(12): p. 14. | Enkel PubMed |
| Ferreira, I.M., et al., Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, 2012. 12: p. CD000998. | Stabiele COPD |
| Firouzabadi, D. and H. Ahmadi, Cancer-Related Malnutrition and the Role of Parenteral Nutrition in Cancer; A Narrative Review. Nutrition & Cancer, 2024. 76(10): p. 870-884. | Narrative review, geen kwaliteitsbeoordeling van geïnccludeerde studies |
| Fortin, A., et al. A randomised study comparing prophylactic gastrostomy to feeding tube as needed in head and neck carcinomas. European journal of cancer, 2013. 49, S760 DOI: 10.1016/S0959-8049(13)70065-0. | Geen full-text |
| Gavazzi, C., et al., Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: A multicentre randomised clinical trial. European Journal of Cancer, 2016. 64: p. 107-12. | Kandidaat voor electieve chirurgie |
| Gibbons, C., et al. Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews, 2018. DOI: 10.1002/14651858.CD011005.pub2. | Gaat niet over voedingsinterventies |
| Gnagnarella P, Misotti AM, Santoro L, et al. (2016) Nutritional online information for cancer patients: a randomized trial of an internet communication plus social media intervention. J Cancer Educ 31, 472–480 | Foute interventie |
| Guerra-Sanchez, L., M. Fresno-Flores, and C. Martinez-Rincon, Effect of a double nutritional intervention on the nutritional status, functional capacity, and quality of life of patients with chronic heart failure: 12-month results from a randomized clinical trial. Nutricion Hospitalaria, 2020. 34(3): p. 422-431. | 85% NYHA II-III |
| Gurgun, A., et al. The effects of nutritional supplementation combined with conventional pulmonary rehabilitation in muscle wasted chronic obstructive pulmonary disease: a prospective, randomized, and controlled study. Chest, 2013. 144, 832a DOI: 10.1378/chest.1701502. | Abstract |
| Haag, G., et al. Open-label, randomized, multicenter, phase IV trial comparing parenteral nutrition using multi-chamber bags (Eurotubes) versus traditional 2/3-chamber bags in subjects with metastatic or locally advanced inoperable cancer requiring parenteral nutrition: the PEKANNUSS trial of the AIO. Journal of clinical oncology, 2020. 38, DOI: 10.1200/JCO.2020.38.15_suppl.TPS7086. | Abstract |

| Referentie | Reden voor exclusie |
|---|---|
| Hariyanto, T.I. and A. Kurniawan, Cachexia in cancer patients: Systematic literature review. <i>Asian Journal of Oncology</i> , 2020. 6(3): p. 107-115. | Geen full-text |
| Herrera-Martinez, A.D., et al., Mediterranean Diet, Vitamin D, and Hypercaloric, Hyperproteic Oral Supplements for Treating Sarcopenia in Patients with Heart Failure-A Randomized Clinical Trial. <i>Nutrients</i> , 2023. 16(1): p. 28. | Dubbel |
| Herrera-Martínez, A.D., et al., Mediterranean Diet, Vitamin D, and Hypercaloric, Hyperproteic Oral Supplements for Treating Sarcopenia in Patients with Heart Failure—A Randomized Clinical Trial. <i>Nutrients</i> , 2024. 16(1). | Onduidelijk hoeveel palliatieve patiënten |
| Herrera-Martinez, A.D., et al., Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial. <i>Nutrients</i> , 2023. 15(12): p. 12. | Onduidelijk hoeveel palliatieve patiënten |
| Hersberger, L., et al., Individualized Nutritional Support for Hospitalized Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021. 77(18): p. 2307-2319. | Secundaire analyse van RCT |
| Huang, J. and C. Li Evaluation of the effects of exercise combined with nutrition support on chronic obstructive pulmonary disease complicated with malnutrition. <i>Practical geriatrics</i> , 2014. 28, 113-116. | Chinees |
| Huang, W.J. and C.Y. Ko, Systematic review and meta-analysis of nutrient supplements for treating sarcopenia in people with chronic obstructive pulmonary disease. <i>Aging-Clinical & Experimental Research</i> , 2024. 36(1): p. 69. | Gericht op sarcopenie |
| Huggins, C., et al. Effect of Early and Intensive Telephone or Electronic Nutrition Counselling Delivered to People with Upper Gastrointestinal Cancer on Quality of Life: a Three-Arm Randomised Controlled Trial. <i>Nutrients</i> , 2022. 14, DOI: 10.3390/nu14153234. | Pre-behandeling voedingsadvies |
| Hummel, S., et al. Geriatric out-of-hospital randomized meal trial in heart failure (GOURMETHF) pilot randomized trial: primary results. <i>Journal of cardiac failure</i> , 2017. 23, 830 DOI: 10.1016/j.cardfail.2017.10.005. | Abstract |
| Ishaq, O., et al. Food as medicine: a randomized controlled trial (RCT) of home delivered, medically tailored meals (HDMTM) on quality of life (QoL) in metastatic lung and noncolorectal GI cancer patients. <i>Journal of clinical oncology</i> , 2016. 34, 155 DOI: 10.1200/jco.2016.34.26-suppl.155. | Abstract |
| Ishiki, H., et al. Oral nutritional support can shorten the duration of parenteral hydration in end-of-life cancer patients: a randomized exploratory trial. <i>European journal of cancer</i> , 2013. 49, S274 DOI: 10.1016/S0959-8049(13)70061-3. | Abstract |
| Jameson, G., et al. Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer: initial results of safety and feasibility of the medically supervised ketogenic diet. <i>Cancer research</i> , 2024. 84, DOI: 10.1158/1538-7445.PANCREATIC24-B012. | Abstract |
| Johal, J., et al., Dietary Supplements in People with Metastatic Cancer Who Are Experiencing Malnutrition, Cachexia, Sarcopenia, and Frailty: A Scoping Review. <i>Nutrients</i> , 2022. 14(13): p. 26. | Gaat enkel over voedings supplementen |
| Kaegi-Braun, N., et al., Nutritional support after hospital discharge improves long-term mortality in malnourished adult medical patients: Systematic review and meta-analysis. <i>Clinical Nutrition</i> , 2022. 41(11): p. 2431-2441. | Palliatieve setting uitgesloten |
| Kasprzyk, A., et al., The Role of Nutritional Support in Malnourished Patients With Lung Cancer. <i>In Vivo</i> , 2021. 35(1): p. 53-60. | Narrative review |

| Referentie | Reden voor exclusie |
|--|---|
| Kenny, E., R. Touger-Decker, and D.A. August, Structured Review of the Value Added by the Registered Dietitian to the Care of Gastrointestinal Cancer Patients. <i>Nutrition in Clinical Practice</i> , 2021. 36(3): p. 606-628. | Meerendeel van de opgenomen studies niet bij palliatieve populatie |
| Khan, N.A., N. Kumar, and M.K. Daga, Effect of dietary supplementation on body composition, pulmonary function and health-related quality of life in patients with stable COPD. <i>Tanaffos</i> , 2016. 15(4): p. 225-235. | Stabiele COPD |
| Kim H, Suh EE, Lee HJ, Yang HK (2014) The effects of patient participation-based dietary intervention on nutritional and functional status for patients with gastrectomy: a randomized controlled trial. <i>Cancer Nurs</i> 37(2):E10–20 | Post-gastrectomie |
| Kim, A.J., D.S. Hong, and G.C. George, Diet-related interventions for cancer-associated cachexia. <i>Journal of Cancer Research & Clinical Oncology</i> , 2021. 147(5): p. 1443-1450. | Narrative review, geen kwaliteitsbeoordeling van geïnccludeerde studies |
| Kiss N, Isenring E, Gough K, et al. (2016) Early and intensive dietary counseling in lung cancer patients receiving (chemo) radiotherapy – a pilot randomized controlled trial. <i>Nutr Cancer</i> 68, 958–967 | Niet-palliatieve populatie |
| Klek, S., et al., Enriched enteral nutrition may improve short-term survival in stage IV gastric cancer patients: A randomized, controlled trial. <i>Nutrition</i> , 2017. 36: p. 46-53. | St. IV maagkanker, maar exclusie van palliatieve resectie |
| Laviano, A., et al. Targeted medical nutrition for cachexia in NSCLC: a randomized, controlled trial. <i>Journal of cachexia, sarcopenia and muscle</i> , 2018. 9, 207-208 DOI: 10.1002/jcsm.12284. | Abstract |
| Laviano, A., et al., Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial. <i>Nutrition and Cancer</i> , 2020. 72(3): p. 439-450. | Geen palliatieve chemotherapie |
| Leedo E, Gade J, Granov S, et al. The effect of a home delivery meal service of energy- and protein rich meals on quality of life in malnourished outpatients suffering from lung cancer: a randomized controlled trial. <i>Nutr Cancer</i> . 2017;69(3):444–453 | 35% st. II-III |
| Li, W., et al. Cost-Effectiveness Analyses of Home Parenteral Nutrition for Incurable Gastrointestinal Cancer Patients. <i>Frontiers in oncology</i> , 2022. 12, DOI: 10.3389/fonc.2022.858712. | CE analysis obv Obling 2019 |
| Li, W., J. Chai, and J. Cui Cost-effectiveness analyses of home parenteral nutrition for incurable gastrointestinal cancer patients. <i>Clinical nutrition ESPEN</i> , 2020. 40, 570 DOI: 10.1016/j.clnesp.2020.09.489. | Abstract |
| Lin, J.X., et al., A multidisciplinary team approach for nutritional interventions conducted by specialist nurses in patients with advanced colorectal cancer undergoing chemotherapy: A clinical trial. <i>Medicine</i> , 2017. 96(26): p. e7373. | >50% st. III |
| Liposits, G., S. Singhal, and J.L. Krok-Schoen, Interventions to improve nutritional status for older patients with cancer - a holistic approach is needed. <i>Current Opinion in Supportive & Palliative Care</i> , 2023. 17(1): p. 15-21. | Enkel PubMed |
| Lopes, H.M., et al., Major outcomes of clinical studies and guidelines on nutritional therapy and palliative care in critically ill patients: a systematic review. <i>International Journal of Nutrology</i> , 2025. 18(2). | Focus op kritiek zieken |
| Matheson, E., et al. Specialized oral nutritional supplement (ONS) improves handgrip strength in hospitalized, malnourished older patients with cardiovascular and pulmonary disease. <i>European geriatric medicine</i> , 2016. 7, S3. | Abstract |

| Referentie | Reden voor exclusie |
|---|--|
| Matheson, E.M., et al., Specialized oral nutritional supplement (ONS) improves handgrip strength in hospitalized, malnourished older patients with cardiovascular and pulmonary disease: A randomized clinical trial. <i>Clinical Nutrition</i> , 2021. 40(3): p. 844-849. | Geen uitkomsten uit PICO |
| Mochamat, Cuhls H, Marinova M, et al. A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project. <i>J Cachexia Sarcopenia Muscle</i> . 2017;8(1):25-39 | Foute interventie |
| Mogelberg, N., et al. The effect of high protein diet in combination with physical activity in the rehabilitation of patients with chronic obstructive pulmonary disease (COPD) a pilot study. <i>Clinical nutrition (Edinburgh, Scotland)</i> , 2014. 33, S71. | Abstract |
| Molassiotis A, Brown T, Cheng HL, Byrnes A, Chan RJ, Wyld D, et al. The effects of a family-centered psychosocial-based nutrition intervention in patients with advanced cancer: the PiCNIC2 pilot randomised controlled trial. <i>Nutr J</i> 2021;20(1):2 | Onduidelijk hoeveel palliatieve patiënten |
| Molassiotis, A., et al. The effects of a family-centered psychosocial-based nutrition intervention in patients with advanced cancer: the PiCNIC2 pilot randomised controlled trial. <i>Asia-Pacific journal of clinical oncology</i> , 2020. 16, 114 DOI: 10.1111/ajco.13498. | Poster |
| Molina, B.E., et al. Nutritional intervention with adapted physical activity (APA) in patients (PTS) with advanced pancreatic cancer (NUTAPACAP): an ancillary of the apacap gercor randomized controlled trial. <i>Clinical nutrition ESPEN</i> , 2024. 63, 1298-1299 DOI: 10.1016/j.clnesp.2024.07.993. | Abstract |
| Morassutti I, Giometto M, Baruffi C, Marcon ML, Michieletto S, Giometto B, et al. Nutritional intervention for amyotrophic lateral sclerosis. <i>Minerva Gastroenterol Dietol</i> 2012;58(3):253-60 | Geen full-text |
| Nguyen, H.T., et al., Effectiveness of Tailored Dietary Counseling in Treating Malnourished Outpatients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. <i>Journal of the Academy of Nutrition & Dietetics</i> , 2020. 120(5): p. 778-791.e1. | 66% met st. III-IV COPD |
| Nguyen, L., et al. Nutrition intervention is beneficial to the quality of life of patients with gastrointestinal cancer undergoing chemotherapy in Vietnam. <i>Cancer medicine</i> , 2021. 10, 1668-1680 DOI: 10.1002/cam4.3766. | Geen RCT |
| Obling, S., et al. Home parenteral nutrition increases fat free mass in patients with incurable gastrointestinal cancer. Results of a randomized controlled trial. <i>Gastroenterology</i> , 2018. 154, S-651 DOI: 10.1016/S0016-5085(18)32316-3. | Abstract |
| Orell-Kotikangas, H., et al. Locally advanced head and neck cancer: the effect of intensive nutrition counseling. <i>Clinical nutrition (Edinburgh, Scotland)</i> , 2013. 32, S157. | Abstract |
| Ortiz Cortes, C., et al., Nutritional intervention in chronic heart failure patients: A randomized controlled clinical trial. <i>Medicina Clinica</i> , 2024. 163(11): p. 549-556. | Meerderheid had NYHA II en was "at nutritional risk" |
| Pai, N., et al. Impact of disease specific nutrition intervention on body composition and food intake in Head and Neck cancer patients. <i>Annals of nutrition & metabolism</i> , 2023. 79, 734 DOI: 10.1159/000530786. | Abstract |
| Paillaud, E., et al., Effectiveness of Geriatric Assessment-Driven Interventions on Survival and Functional and Nutritional Status in Older Patients with Head and Neck Cancer: A Randomized Controlled Trial (EGeSOR). <i>Cancers</i> , 2022. 14(13). | Geen afgelijnde voedingsinterventie |
| Palma, M.S., et al. Impact of nutritional supplementation with bioactive compounds on improving the intake of cancer patients: the Alisenoc study. <i>Clinical nutrition ESPEN</i> , 2023. 58, 618 DOI: 10.1016/j.clnesp.2023.09.564. | Abstract |

| Referentie | Reden voor exclusie |
|---|---|
| Payne, C., P.J. Wiffen, and S. Martin, Interventions for fatigue and weight loss in adults with advanced progressive illness. <i>Cochrane Database of Systematic Reviews</i> , 2012. 1: p. CD008427. | Updated |
| Payne, C., P.J. Wiffen, and S. Martin, Interventions for fatigue and weight loss in adults with advanced progressive illness. <i>Cochrane Database of Systematic Reviews</i> , 2017. 2017(4). | Withdrawn |
| Poulsen, G.M., et al., Randomized trial of the effects of individual nutritional counseling in cancer patients. <i>Clinical Nutrition</i> , 2014. 33(5): p. 749-53. | Onduidelijk hoeveel palliatieve patiënten |
| Prokopidis, K., et al., Exercise and nutritional interventions on sarcopenia and frailty in heart failure: a narrative review of systematic reviews and meta-analyses. <i>ESC heart failure</i> , 2022. 9(5): p. 2787-2799. | Narrative review |
| Radhika, D., A. Muthukrishnan, and R. Issrani, Nutritional Supportive Care in Head and Neck Cancer Patients – A Narrative Review. <i>Iranian Journal of Blood and Cancer</i> , 2024. 16(4): p. 105-113. | Narrative review |
| Raizada, N., et al. Nutritional intervention in stable COPD patients and its effect on anthropometry, pulmonary function, and health-related quality of life (HRQL). <i>Journal, indian academy of clinical medicine</i> , 2014. 15, 100-105. | Stabiele COPD |
| Rakel, B.T., et al. Feasibility of dietary counseling to attenuate cachexia in patients with advanced cancer. <i>Clinical nutrition (Edinburgh, Scotland)</i> , 2014. 33, S53. | Abstract |
| Ramiro-Ortega, E., et al., Nutritional intervention in acute heart failure patients with undernutrition and normalalbuminemia: A subgroup analysis of PICNIC study. <i>Clinical Nutrition</i> , 2018. 37(5): p. 1762-1764. | Post-hoc analyse |
| Ravasco P, Monteiro-Grillo I, Camilo M (2012) Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. <i>Am J Clin Nutr</i> 96(6):1346–1353 | Neoadjuvante radiotherapie |
| Regueme SC, Echeverria I, Mon´eger N, Durrieu J, Becerro-Hallard M, Duc S, et al. Protein intake, weight loss, dietary intervention, and worsening of quality of life in older patients during chemotherapy for cancer. <i>Support Care Cancer Off J Multinatl Assoc Support Care Cancer</i> 2021;29:687–96 | Onduidelijk hoeveel palliatieve patiënten |
| Regueme, S., N. Moneger, and I. Bourdel-Marchasson Quality of life outcomes in older people treated with chemotherapy for cancer at risk for malnutrition and included in a randomized control trial of nutritional advices. <i>European geriatric medicine</i> , 2016. 7, S194. | Geen full-text |
| Richards, J., et al., Impact of Early Incorporation of Nutrition Interventions as a Component of Cancer Therapy in Adults: A Review. <i>Nutrients</i> , 2020. 12(11): p. 05. | Patiënten gepland voor actieve kankerbehandeling |
| Richter E, Denecke A, Klapdor S, et al. Parenteral nutrition support for patients with pancreatic cancer—improvement of the nutritional status and the therapeutic outcome. <i>Anticancer Res.</i> 2012;32:2111–2118 | Geen RCT |
| Rocha, R.R.P. and T. Caetano, Major considerations of nutrological therapy in cancer patients: a systematic review. <i>International Journal of Nutrology</i> , 2024. 17. | Narrative review, geen kwaliteitsbeoordeling van geïnccludeerde studies |
| Roy, S., et al. Effectiveness of tailored diet plan on nutritional status among cancer patients discharged with nasogastric tube in India - A randomized controlled trial. <i>Clinical nutrition ESPEN</i> , 2024. 63, 1181 DOI: 10.1016/j.clnesp.2024.07.645. | Abstract |

| Referentie | Reden voor exclusie |
|--|---|
| Sadasivan, A.; Faizal, B.; Kumar, M. Nasogastric and percutaneous endoscopic gastrostomy tube use in advanced head and neck cancer patients: A comparative study. <i>J. Pain Palliat. Care Pharmacother.</i> 2012, 26, 226–232 | St. II-III HH tumoren |
| Saijo T, Yasumoto K, Ohashi M, Momoki C, Habu D. Association between early enteral nutrition and clinical outcome in patients with severe acute heart failure who require invasive mechanical ventilation. <i>JPEN J Parenter Enteral Nutr.</i> 2022 Feb;46(2):443-453 | Foute populatie |
| Sathiaraj, E., et al. Effects of nutrition intervention using nutrition care process on fatigue in patients undergoing chemotherapy – a randomized controlled pilot study. <i>Clinical nutrition ESPEN</i> , 2020. 40, 423 DOI: 10.1016/j.clnesp.2020.09.059. | Abstract |
| Savva, J., et al. Exploring potential benefit of earlier nutritional interventions in adults with upper gastrointestinal cancer: a randomised trial. <i>Asia-Pacific journal of clinical oncology</i> , 2013. 9, 73 DOI: 10.1111/ajco.12144. | Abstract |
| Schuetz, P., et al. In-Hospital Nutritional Support Proves Cost-Effective For Malnourished Patients With Cancer. <i>Clinical nutrition ESPEN</i> , 2023. 54, 472 DOI: 10.1016/j.clnesp.2022.09.052. | Abstract |
| Schuetz, P., et al., Economic Evaluation of Individualized Nutritional Support for Hospitalized Patients with Chronic Heart Failure. <i>Nutrients</i> , 2022. 14(9): p. 20. | Economische analyse |
| Shahid, T., et al. To compare outcome of Intensive nutritional support with standard practise in head and neck cancer. <i>Radiotherapy and oncology</i> , 2019. 133, S642 DOI: 10.1016/S0167-8140(19)31579-8. | Abstract |
| She, G., X. Kuang, and Y. Shi Application of the Diet and Nutrition Management System in the Nutrition Management of Tumor Patients Treated with Chemotherapy. <i>Anti-tumor pharmacy</i> , 2018. 8, 292-295 and 300 DOI: 10.3969/j.issn.2095-1264.2018.02.38. | Geen full-text |
| Shusterman, M., et al. Phase II randomized controlled trial (RCT) of medical intensive nutrition therapy (MINT) to improve chemotherapy (CT) tolerability in malnourished patients with solid tumor malignancies. <i>Journal of clinical oncology</i> , 2020. 38, DOI: 10.1200/jco.2020.38.15_suppl.12090. | Abstract |
| Silander, E., et al., Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. <i>Head & Neck</i> , 2012. 34(1): p. 1-9. | Behandeling met curatieve intent |
| Silver, M. Is the dash diet the optimal diet for heart failure patients? <i>Cardiology (switzerland)</i> , 2014. 128, 420 DOI: 10.1159/000365062. | Abstract |
| Silvers, M., et al. Exploring potential benefit of earlier nutritional interventions in adults with upper gastrointestinal cancer: a randomised trial. <i>Supportive care in cancer</i> , 2015. 23, S172-s173 DOI: 10.1007/s00520-015-2712-y. | Pre-behandeling voedingsadvies |
| Sim, E., et al., The Effect of Omega-3 Enriched Oral Nutrition Supplement on Nutritional Indices and Quality of Life in Gastrointestinal Cancer Patients: A Randomized Clinical Trial. <i>Asian Pacific Journal of Cancer Prevention: Apjcp</i> , 2022. 23(2): p. 485-494. | Onduidelijk hoeveel palliatieve patiënten |
| Syahrudin, E. and O. Khonsa Effect of oral nutritional supplement formula and dietary counselling on improving nutritional status of gynaecology cancer patients. <i>Annals of oncology</i> , 2024. 35, S1605 DOI: 10.1016/j.annonc.2024.10.585. | Abstract |
| Syahrudin, E., et al., The Impact of Oral Nutrition Supplementation and Dietary Education on Nutritional Status, Knowledge, Attitudes, and Behaviour in Cancer Patients: A Randomized Clinical Trial. <i>Nutrition & Cancer</i> , 2025. 77(4-5): p. 474-482. | Onduidelijk hoeveel palliatieve patiënten |
| Tu, M.Y., et al., Effects of an intervention on nutrition consultation for cancer patients. <i>European Journal of Cancer Care</i> , 2013. 22(3): p. 370-6. | Geen palliatieve populatie |

| Referentie | Reden voor exclusie |
|---|--|
| Ukovic, B. and J. Porter, Nutrition interventions to improve the appetite of adults undergoing cancer treatment: a systematic review. <i>Supportive Care in Cancer</i> , 2020. 28(10): p. 4575-4583. | Niet noodzakelijk malnutritie |
| Uster, A., et al., Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial. <i>Nutrition</i> , 2013. 29(11-12): p. 1342-9. | Onduidelijk hoeveel palliatieve patiënten |
| van Beers, M., et al., Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass: The randomized controlled NUTRAIN trial. <i>Clinical Nutrition</i> , 2020. 39(2): p. 405-413. | Focus op sarcopenie |
| Van, D.B.C., et al. Physiological effects of nutritional supplementation as adjunct to exercise training in COPD patients with low muscle mass. The double blind, placebo controlled multi-centre NUTRAIN-trial. <i>European respiratory journal</i> , 2016. 48, DOI: 10.1183/13993003.congress-2016.OA266. | Abstract |
| Vashi P, Popiel B, Lammersfeld C, et al. Outcomes of systematic nutritional assessment and medical nutrition therapy in pancreatic cancer. <i>Pancreas</i> . 2015;44:750–755 | Geen RCT |
| Vidal, C.A., et al. Impact of an oral nutritional supplement with bioactive compounds on improving nutritional status, body composition and quality of life in cancer patients: the ALISENOC study. <i>Clinical nutrition ESPEN</i> , 2023. 58, 493 DOI: 10.1016/j.clnesp.2023.09.200. | Abstract |
| Wang, R., J. Deng, and L. Yang Influence of enteral nutrition on cardiac function and inflammatory factors in elderly patients with chronic pulmonary heart failure. <i>Journal of the American Geriatrics Society</i> , 2013. 61, S316 DOI: 10.1111/jgs.12439. | Geen full-text |
| Wei B, Xiong ZF, Chen JS. Combined parenteral and enteral nutrition support with chemotherapy in treating elderly patients with advanced gastrointestinal cancer. <i>Chinese Journal of Clinical Nutrition</i> 2013;21(2):72-6 | Chinees |
| Wills A-M, Garry J, Hubbard J, Mezoian T, Xie J, Breen C, et al. Effects of dietary counseling on nutrient consumption from the electronic health application to measure outcomes remotely (EAT MORE) study. <i>Amyotroph Lateral Scler Frontotemporal Degener</i> 2017;18(Suppl. 2):300 | Geen full-text |
| Xie, F.L., et al., Beneficial Effect of Educational and Nutritional Intervention on the Nutritional Status and Compliance of Gastric Cancer Patients Undergoing Chemotherapy: A Randomized Trial. <i>Nutrition & Cancer</i> , 2017. 69(5): p. 762-771. | Slechts ongeveer 10% st. IV |
| Yoon, S.L. and O. Grundmann, Relevance of Dietary Supplement Use in Gastrointestinal-Cancer-Associated Cachexia. <i>Nutrients</i> , 2023. 15(15): p. 30. | Gaat enkel over voedingssupplementen |
| Zeng, X., et al., The application of the PDCA cycle in the nutritional management of patients with nasopharyngeal carcinoma. <i>Supportive Care in Cancer</i> , 2023. 31(5): p. 251. | Behandeling met radiotherapie, niet allemaal malnutritie |
| Zhang D, Li H, Tian X, Zhang S. Effects of enteral nutrition on heart function, inflammatory markers and immune function in elderly patients with chronic heart failure. <i>Pak J Med Sci</i> . 2022 Jan-Feb;38(1):302-309 | Foute populatie |
| Zhang, Z., et al., Nutritional education and counseling program for adult cancer patients during radiotherapy: a cluster-randomized clinical trial. <i>Supportive Care in Cancer</i> , 2022. 30(4): p. 3279-3289. | Minderheid had st. IV kanker |
| Zheng, H.Y., et al., Efficacy of nutrient supplements in managing malnutrition and sarcopenia in Chronic Obstructive Pulmonary Disease (COPD) patients: a protocol for systematic review and meta-analysis. <i>Systematic Reviews</i> , 2025. 14(1): p. 58. | Protocol |
| Zhong, Y., et al., The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. <i>Applied Health Economics and Health Policy</i> , 2017. 15(1): p. 75-83. | CE analysis obv Deutz 2016 |

| Referentie | Reden voor exclusie |
|---|--|
| Zhou, H. and H. Qian, Relationship between enteral nutrition and serum levels of inflammatory factors and cardiac function in elderly patients with heart failure. <i>Clinical Interventions In Aging</i> , 2018. 13: p. 397-401. | Geen NYHA IV |
| Zietarska, M., et al., Chemotherapy-Related Toxicity, Nutritional Status and Quality of Life in Precachectic Oncologic Patients with, or without, High Protein Nutritional Support. A Prospective, Randomized Study. <i>Nutrients</i> , 2017. 9(10): p. 11. | Pre-cachexie, geen palliatieve populatie |
| Zong, M., et al., Effects of whey protein complex combined with low-intensity exercise in elderly inpatients with COPD at a stable stage. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2023. 32(4): p. 375-382. | Stabiele COPD |

Onderzoeksvraag 2: Medicamenteuze interventies

Onderzoeksvraag

Wat is het effect van medicamenteuze interventies op gewichtsverlies en kwaliteit van leven bij patiënten met kanker, hartfalen, COPD en ALS?

| | |
|---|---|
| P | Patiënten met gevorderde kanker, hartfalen, ALS of COPD, en anorexie / gewichtsverlies |
| I | Medicamenteuze interventies: progestativa (megestrol, medroxyprogesteronacetaat), corticosteroïden (dexamethason, predniso(lo)n, methylprednisolon), cannabinoïden (cannabisextract, dronabinol, tetrahydrocannabinol), NSAID's (indometacine, ibuprofen), androgene steroïden (nandrolone, oxandrol), enobosarm, prokinetica (metoclopramide), mirtazapine, olanzapine, hydrazine, cyproheptadine, pentoxifylline, melatonine, erythropoëetine, eicosapentanoïnezuur (EPA), visolie, omega-3 polyunsaturated fatty acids, ghreline, anamoreline, interferon, thalidomide, ATP, etanercept, onsegregromab, anti-TNF-alfa antilichamen (infliximab), carnitine, insuline, espidolol, tocilizumab |
| C | Placebo, geen of andere medicamenteuze interventies |
| O | Cruciaal: gewichtsverlies / gewicht, anorexie / eetlust Belangrijk: bijwerkingen, voedsel / calorie inname, lean body mass, kwaliteit van leven, performance status, overleving |

Ovid MEDLINE(R) <1946 to April 09, 2025>

- 1 exp Neoplasms/ (4094844)
- 2 Neoplasm Staging/ (200746)
- 3 cancer\$.ti,ab. (2068768)
- 4 tumor\$.ti,ab. (1617010)
- 5 tumour\$.ti,ab. (289392)
- 6 carcinoma\$.ti,ab. (702367)
- 7 neoplasm\$.ti,ab. (144144)
- 8 lymphoma.ti,ab. (171729)
- 9 melanoma.ti,ab. (124187)
- 10 staging.ti,ab. (87308)
- 11 metastas\$.ti,ab. (398158)
- 12 metastatic.ti,ab. (252282)
- 13 exp Neoplasm Metastasis/ (229716)
- 14 exp neoplastic processes/ (539522)
- 15 neoplastic process\$.ti,ab. (3009)
- 16 non small cell.ti,ab. (74025)
- 17 adenocarcinoma\$.ti,ab. (162139)
- 18 squamous cell.ti,ab. (119224)
- 19 nsclc.ti,ab. (52296)
- 20 osteosarcoma\$.ti,ab. (25925)

- 21 phyllodes.ti,ab. (2076)
- 22 cystosarcoma\$.ti,ab. (569)
- 23 fibroadenoma\$.ti,ab. (3737)
- 24 (non adj small adj cell).ti,ab. (74025)
- 25 (non adj2 small adj2 cell).ti,ab. (74277)
- 26 (nonsmall adj2 cell).ti,ab. (3406)
- 27 plasmacytoma\$.ti,ab. (6444)
- 28 myeloma.ti,ab. (57037)
- 29 multiple myeloma.ti,ab. (42142)
- 30 lymphoblastoma\$.ti,ab. (346)
- 31 lymphocytoma\$.ti,ab. (343)
- 32 lymphosarcoma\$.ti,ab. (4086)
- 33 immunocytoma.ti,ab. (404)
- 34 sarcoma\$.ti,ab. (99835)
- 35 hodgkin\$.ti,ab. (66674)
- 36 (nonhodgkin\$ or non hodgkin\$).ti,ab. (38631)
- 37 malignan\$.ti,ab. (626334)
- 38 or/1-37 (4882127)
- 39 exp Heart Failure/ (159248)
- 40 (heart adj2 failure*).tw. (199178)
- 41 (cardiac adj2 failure*).tw. (15605)
- 42 (myocardial adj2 failure*).tw. (3651)
- 43 (heart adj2 decompensat*).tw. (4898)
- 44 heart failure.tw. (198376)
- 45 cardiac failure.tw. (11995)
- 46 or/39-45 (252123)
- 47 Lung Diseases, Obstructive/ (18314)
- 48 exp Pulmonary Disease, Chronic Obstructive/ (71988)
- 49 emphysema\$.mp. (37445)
- 50 (chronic\$ adj3 bronchiti\$).mp. (11686)
- 51 (obstruct\$ adj3 (pulmonary or lung\$ or airway\$ or airflow\$ or bronch\$ or respirat\$)).mp. (133488)
- 52 COPD.mp. (55595)
- 53 COAD.mp. (914)
- 54 COBD.mp. (22)
- 55 AECB.mp. (218)
- 56 or/47-55 (174533)
- 57 exp Amyotrophic Lateral Sclerosis/ (25480)
- 58 ALS.ti,ab. (43201)
- 59 Motor Neuron Disease/ (4977)
- 60 "Charcot disease".ti,ab. (24)
- 61 "Lou Gehrig".ti,ab. (25)
- 62 or/57-61 (54183)
- 63 38 or 46 or 56 or 62 (5311517)
- 64 Anorexia/ (5602)
- 65 Weight Loss/ (47184)
- 66 anorexi*.ti,ab. (35579)
- 67 (cachex* or cachect*).ti,ab. (9938)
- 68 (malnourish* or malnutrition or emaciation or "weight loss" or underweight or wasting or wasted or appetite or starvation).ti,ab. (235521)
- 69 Cachexia/ (6779)
- 70 Appetite/ (9158)
- 71 or/64-70 (285045)
- 72 63 and 71 (54319)

- 73 exp Progesterone Congeners/ (73570)
- 74 exp Megestrol/ (1727)
- 75 exp Medroxyprogesterone/ (7516)
- 76 (megestrol* or medroxyprogesteron*).ti,ab. (7681)
- 77 exp Adrenal Cortex Hormones/ (436079)
- 78 corticosteroid*.ti,ab. (112657)
- 79 Dexamethasone/ (57501)
- 80 Prednisolone/ (34860)
- 81 Prednisone/ (42005)
- 82 Methylprednisolone/ (20678)
- 83 (dexamethason* or prednison* or prednisolon* or methylprednisolon*).ti,ab. (128127)
- 84 exp Cannabinoids/ (20105)
- 85 Cannabis/ (15618)
- 86 (cannabi* or dronabinol or THC or tetrahydrocannabinol).ti,ab. (49036)
- 87 exp Anti-Inflammatory Agents, Non-Steroidal/ (224045)
- 88 Indomethacin/ (29088)
- 89 Ibuprofen/ (10623)
- 90 (NSAID* or indomet?acin* or ibuprofen).ti,ab. (72605)
- 91 exp Nandrolone/ (3087)
- 92 Oxandrolone/ (488)
- 93 exp Testosterone Congeners/ (98094)
- 94 (androgen* or nandrolon* or oxandrol or enobosarm).ti,ab. (87494)
- 95 Metoclopramide/ (5040)
- 96 (prokinetic* or metoclopramide).ti,ab. (8569)
- 97 Mirtazapine/ (1567)
- 98 mirtazapin*.ti,ab. (2293)
- 99 Olanzapine/ (6509)
- 100 olanzapin*.ti,ab. (8696)
- 101 exp Hydrazines/ (53250)
- 102 hydrazin*.ti,ab. (8886)
- 103 exp Cyproheptadine/ (3461)
- 104 cyproheptadin*.ti,ab. (2296)
- 105 Pentoxifylline/ (4474)
- 106 pentoxifyllin*.ti,ab. (4529)
- 107 Melatonin/ (24871)
- 108 melatonin*.ti,ab. (28327)
- 109 exp Erythropoietin/ (25081)
- 110 (erythropoetin* or EPO).ti,ab. (12265)
- 111 Eicosapentaenoic Acid/ (7651)
- 112 Fish Oils/ (8814)
- 113 exp Fatty Acids/ (515585)
- 114 (eicosapentaen* or docosahexaen* or "omega-3" or (fatty adj1 acid*) or EPA or (oil* adj6 (cod* or marin* or fish*))).ti,ab. (273351)
- 115 Ghrelin/ (8788)
- 116 (ghrelin or ppghrelin or (motilin adj2 peptide) or ghrl or obestatin or ppmtlrp or "appetite regulating hormone" or Anamorelin or Ipamorelin or Eganamorelin or Hexarelin or MK-677 or Rikkunshito).ti,ab. (11629)
- 117 anamorelin*.ti,ab. (102)
- 118 exp Interferons/ (148871)
- 119 (interferon or INF).ti,ab. (167006)
- 120 Thalidomide/ (10117)
- 121 thalidomid*.ti,ab. (8079)
- 122 Etanercept/ (6681)

123 etanercept.ti,ab. (7166)
 124 ponesgromab.ti,ab. (6)
 125 exp Antibodies, Monoclonal/ (294347)
 126 infliximab.ti,ab. (13138)
 127 exp Carnitine/ (11230)
 128 carnitin*.ti,ab. (16878)
 129 exp Insulins/ (213315)
 130 insulin.ti,ab. (385295)
 131 espidolol.ti,ab. (1)
 132 tocilizumab.ti,ab. (5227)
 133 Interleukin-6/ (81044)
 134 IL6.ti,ab. (10621)
 135 or/73-134 (2605152)
 136 randomized controlled trial.pt. (635062)
 137 controlled clinical trial.pt. (95668)
 138 randomized.ab. (586921)
 139 placebo.ab. (232304)
 140 clinical trials as topic.sh. (204747)
 141 randomly.ab. (378907)
 142 trial.ti. (284868)
 143 136 or 137 or 138 or 139 or 140 or 141 or 142 (1478663)
 144 exp animals/ not humans.sh. (5325645)
 145 143 not 144 (1348079)
 146 meta-analysis.mp,pt. or review.pt. or search:.tw. (3507404)
 147 145 or 146 (4616550)
 148 72 and 135 and 147 (3765)

Ovid MEDLINE(R) Epub Ahead of Print <April 09, 2025>

Ovid MEDLINE(R) Daily Update <April 09, 2025>

1 exp Neoplasms/ (2351)
 2 Neoplasm Staging/ (89)
 3 cancer\$.ti,ab. (30196)
 4 tumor\$.ti,ab. (18148)
 5 tumour\$.ti,ab. (2255)
 6 carcinoma\$.ti,ab. (6874)
 7 neoplasm\$.ti,ab. (1831)
 8 lymphoma.ti,ab. (1861)
 9 melanoma.ti,ab. (1377)
 10 staging.ti,ab. (1278)
 11 metastas\$.ti,ab. (4827)
 12 metastatic.ti,ab. (3189)
 13 exp Neoplasm Metastasis/ (110)
 14 exp neoplastic processes/ (233)
 15 neoplastic process\$.ti,ab. (24)
 16 non small cell.ti,ab. (1186)
 17 adenocarcinoma\$.ti,ab. (1848)
 18 squamous cell.ti,ab. (1564)
 19 nsclc.ti,ab. (866)
 20 osteosarcoma\$.ti,ab. (247)
 21 phyllodes.ti,ab. (17)
 22 cystosarcoma\$.ti,ab. (2)
 23 fibroadenoma\$.ti,ab. (78)
 24 (non adj small adj cell).ti,ab. (1186)

25 (non adj2 small adj2 cell).ti,ab. (1187)
 26 (nonsmall adj2 cell).ti,ab. (45)
 27 plasmacytoma\$.ti,ab. (36)
 28 myeloma.ti,ab. (599)
 29 multiple myeloma.ti,ab. (537)
 30 lymphoblastoma\$.ti,ab. (0)
 31 lymphocytoma\$.ti,ab. (5)
 32 lymphosarcoma\$.ti,ab. (2)
 33 immunocytoma.ti,ab. (1)
 34 sarcoma\$.ti,ab. (907)
 35 hodgkin\$.ti,ab. (478)
 36 (nonhodgkin\$ or non hodgkin\$).ti,ab. (289)
 37 malignan\$.ti,ab. (7430)
 38 or/1-37 (47267)
 39 exp Heart Failure/ (88)
 40 (heart adj2 failure*).tw. (3333)
 41 (cardiac adj2 failure*).tw. (140)
 42 (myocardial adj2 failure*).tw. (56)
 43 (heart adj2 decompensat*).tw. (87)
 44 heart failure.tw. (3328)
 45 cardiac failure.tw. (81)
 46 or/39-45 (3429)
 47 Lung Diseases, Obstructive/ (0)
 48 exp Pulmonary Disease, Chronic Obstructive/ (42)
 49 emphysema\$.mp. (267)
 50 (chronic\$ adj3 bronchiti\$).mp. (61)
 51 (obstruct\$ adj3 (pulmonary or lung\$ or airway\$ or airflow\$ or bronch\$ or respirat\$)).mp. (1283)
 52 COPD.mp. (864)
 53 COAD.mp. (25)
 54 COBD.mp. (0)
 55 AECB.mp. (0)
 56 or/47-55 (1723)
 57 exp Amyotrophic Lateral Sclerosis/ (18)
 58 ALS.ti,ab. (1144)
 59 Motor Neuron Disease/ (3)
 60 "Charcot disease".ti,ab. (0)
 61 "Lou Gehrig".ti,ab. (0)
 62 or/57-61 (1146)
 63 38 or 46 or 56 or 62 (52852)
 64 Anorexia/ (3)
 65 Weight Loss/ (64)
 66 anorexi*.ti,ab. (391)
 67 (cachex* or cachect*).ti,ab. (109)
 68 (malnourish* or malnutrition or emaciation or "weight loss" or underweight or wasting or wasted or appetite
 or starvation).ti,ab. (3430)
 69 Cachexia/ (2)
 70 Appetite/ (2)
 71 or/64-70 (3769)
 72 63 and 71 (695)
 73 exp Progesterone Congeners/ (8)
 74 exp Megestrol/ (1)
 75 exp Medroxyprogesterone/ (2)
 76 (megestrol* or medroxyprogesteron*).ti,ab. (38)

- 77 exp Adrenal Cortex Hormones/ (114)
- 78 corticosteroid*.ti,ab. (1508)
- 79 Dexamethasone/ (24)
- 80 Prednisolone/ (5)
- 81 Prednisone/ (9)
- 82 Methylprednisolone/ (7)
- 83 (dexamethason* or prednison* or prednisolon* or methylprednisolon*).ti,ab. (1050)
- 84 exp Cannabinoids/ (9)
- 85 Cannabis/ (11)
- 86 (cannabi* or dronabinol or THC or tetrahydrocannabinol).ti,ab. (1054)
- 87 exp Anti-Inflammatory Agents, Non-Steroidal/ (69)
- 88 Indomethacin/ (1)
- 89 Ibuprofen/ (5)
- 90 (NSAID* or indomet?acin* or ibuprofen).ti,ab. (597)
- 91 exp Nandrolone/ (0)
- 92 Oxandrolone/ (0)
- 93 exp Testosterone Congeners/ (24)
- 94 (androgen* or nandrolon* or oxandrol or enobosarm).ti,ab. (907)
- 95 Metoclopramide/ (1)
- 96 (prokinetic* or metoclopramide).ti,ab. (84)
- 97 Mirtazapine/ (1)
- 98 mirtazapin*.ti,ab. (50)
- 99 Olanzapine/ (2)
- 100 olanzapin*.ti,ab. (138)
- 101 exp Hydrazines/ (12)
- 102 hydrazin*.ti,ab. (162)
- 103 exp Cyproheptadine/ (1)
- 104 cyproheptadin*.ti,ab. (11)
- 105 Pentoxifylline/ (0)
- 106 pentoxifyllin*.ti,ab. (24)
- 107 Melatonin/ (18)
- 108 melatonin*.ti,ab. (364)
- 109 exp Erythropoietin/ (5)
- 110 (erythropoetin* or EPO).ti,ab. (79)
- 111 Eicosapentaenoic Acid/ (0)
- 112 Fish Oils/ (5)
- 113 exp Fatty Acids/ (161)
- 114 (eicosapentaen* or docosahexaen* or "omega-3" or (fatty adj1 acid*) or EPA or (oil* adj6 (cod* or marin* or fish*))).ti,ab. (2809)
- 115 Ghrelin/ (1)
- 116 (ghrelin or ppghrelin or (motilin adj2 peptide) or ghrl or obestatin or ppmtlpr or "appetite regulating hormone" or Anamorelin or Ipamorelin or Eganamorelin or Hexarelin or MK-677 or Rikkunshito).ti,ab. (72)
- 117 anamorelin*.ti,ab. (3)
- 118 exp Interferons/ (48)
- 119 (interferon or INF).ti,ab. (1101)
- 120 Thalidomide/ (4)
- 121 thalidomid*.ti,ab. (61)
- 122 Etanercept/ (0)
- 123 etanercept.ti,ab. (87)
- 124 ponesegromab.ti,ab. (1)
- 125 exp Antibodies, Monoclonal/ (161)
- 126 infliximab.ti,ab. (190)
- 127 exp Carnitine/ (5)

- 128 carnitin*.ti,ab. (161)
- 129 exp Insulins/ (51)
- 130 insulin.ti,ab. (3158)
- 131 espindolol.ti,ab. (0)
- 132 tocilizumab.ti,ab. (145)
- 133 Interleukin-6/ (30)
- 134 IL6.ti,ab. (180)
- 135 or/73-134 (13458)
- 136 randomized controlled trial.pt. (428)
- 137 controlled clinical trial.pt. (2)
- 138 randomized.ab. (9876)
- 139 placebo.ab. (2429)
- 140 clinical trials as topic.sh. (44)
- 141 randomly.ab. (4762)
- 142 trial.ti. (4871)
- 143 136 or 137 or 138 or 139 or 140 or 141 or 142 (16536)
- 144 exp animals/ not humans.sh. (1939)
- 145 143 not 144 (16461)
- 146 meta-analysis.mp,pt. or review.pt. or search:.tw. (58768)
- 147 145 or 146 (71021)
- 148 72 and 135 and 147 (35)

Cochrane Library: 10-04-2025

- #1 MeSH descriptor: [Neoplasms] explode all trees 126627
- #2 MeSH descriptor: [Neoplasm Staging] explode all trees 9902
- #3 cancer*.ti,ab 192504
- #4 tumor*.ti,ab 71986
- #5 tumour*.ti,ab 15585
- #6 carcinoma*.ti,ab 37639
- #7 neoplasm*.ti,ab 10071
- #8 lymphoma:ti,ab 11380
- #9 melanoma:ti,ab 6375
- #10 staging:ti,ab 6909
- #11 metastas*.ti,ab 23292
- #12 metastatic:ti,ab 36719
- #13 MeSH descriptor: [Neoplasm Metastasis] explode all trees 7622
- #14 MeSH descriptor: [Neoplastic Processes] explode all trees 15481
- #15 neoplastic process*.ti,ab 222
- #16 (non NEAR small NEAR cell):ti,ab 14755
- #17 adenocarcinoma*.ti,ab 10710
- #18 (squamous NEAR cell):ti,ab 9398
- #19 nslc:ti,ab 12850
- #20 osteosarcoma*.ti,ab 508
- #21 phyllodes:ti,ab 6
- #22 cystosarcoma*.ti,ab 0
- #23 fibroadenoma*.ti,ab 116
- #24 (non NEAR/2 small NEAR/2 cell):ti,ab 14729
- #25 (nonsmall NEAR/2 cell):ti,ab 11738
- #26 plasmacytoma*.ti,ab 145
- #27 myeloma:ti,ab 6788
- #28 (multiple NEAR myeloma):ti,ab 6175
- #29 lymphoblastoma*.ti,ab 0
- #30 lymphocytoma*.ti,ab 1

| | | |
|-----|--|--------|
| #31 | lymphosarcoma*.ti,ab | 22 |
| #32 | immunocytoma.ti,ab | 17 |
| #33 | sarcoma*.ti,ab | 2979 |
| #34 | hodgkin*.ti,ab | 5843 |
| #35 | (nonhodgkin* or (non NEAR hodgkin*)):ti,ab | 3532 |
| #36 | malignan*.ti,ab | 32473 |
| #37 | {or #1-#36} | 298353 |
| #38 | MeSH descriptor: [Heart Failure] explode all trees | 14728 |
| #39 | (heart and failure*):ti,ab | 38322 |
| #40 | (cardiac and failure*):ti,ab | 15872 |
| #41 | (myocardial and failure*):ti,ab | 9918 |
| #42 | (heart and decompensat*):ti,ab | 2094 |
| #43 | #38 or #39 or #40 or #41 or #42 | 44320 |
| #44 | MeSH descriptor: [Lung Diseases, Obstructive] explode all trees | 25209 |
| #45 | MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] 1 tree(s) exploded | 7996 |
| #46 | emphysema*.ti,ab | 1558 |
| #47 | (chronic* NEAR/3 bronchiti*):ti,ab | 2015 |
| #48 | (obstruct* NEAR/3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)):ti,ab | 19220 |
| #49 | COPD.ti,ab | 19875 |
| #50 | COAD.ti,ab | 101 |
| #51 | COBD.ti,ab | 2 |
| #52 | AECB.ti,ab | 139 |
| #53 | #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 | 44732 |
| #54 | MeSH descriptor: [Amyotrophic Lateral Sclerosis] explode all trees | 893 |
| #55 | ALS.ti,ab | 2480 |
| #56 | MeSH descriptor: [Motor Neuron Disease] this term only | 381 |
| #57 | "Charcot disease".ti,ab | 2 |
| #58 | "Lou Gehrig".ti,ab | 10 |
| #59 | {or #54-#58} | 2663 |
| #60 | #37 or #43 or #53 or #59 | 383729 |
| #61 | MeSH descriptor: [Anorexia] explode all trees | 530 |
| #62 | MeSH descriptor: [Weight Loss] explode all trees | 9086 |
| #63 | anorexi*.ti,ab | 4194 |
| #64 | (cachex* or cachect*):ti,ab | 970 |
| #65 | (malnourish* or malnutrition or emaciation or "weight loss" or underweight or wasting or wasted or appetite or starvation):ti,ab | 40192 |
| #66 | MeSH descriptor: [Cachexia] explode all trees | 415 |
| #67 | MeSH descriptor: [Appetite] explode all trees | 1932 |
| #68 | {or #61-#67} | 45715 |
| #69 | #60 and #68 | 8789 |
| #70 | MeSH descriptor: [Progesterone Congeners] explode all trees | 3105 |
| #71 | MeSH descriptor: [Megestrol] explode all trees | 386 |
| #72 | MeSH descriptor: [Medroxyprogesterone] explode all trees | 1455 |
| #73 | (megestrol* or medroxyprogesteron*):ti,ab | 2627 |
| #74 | MeSH descriptor: [Adrenal Cortex Hormones] explode all trees | 18870 |
| #75 | corticosteroid*.ti,ab | 26177 |
| #76 | MeSH descriptor: [Dexamethasone] explode all trees | 6253 |
| #77 | MeSH descriptor: [Prednisolone] explode all trees | 5892 |
| #78 | MeSH descriptor: [Prednisone] explode all trees | 4821 |
| #79 | (dexamethason* or prednison* or prednisolon* or methylprednisolon*):ti,ab | 33258 |
| #80 | MeSH descriptor: [Cannabinoids] explode all trees | 1563 |
| #81 | MeSH descriptor: [Cannabis] explode all trees | 647 |
| #82 | MeSH descriptor: [Dronabinol] explode all trees | 1050 |

| | | | |
|------|---|--------|------|
| #83 | (cannabi* or dronabinol or THC or tetrahydrocannabinol):ti,ab | 5002 | |
| #84 | MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees | | 9413 |
| #85 | MeSH descriptor: [Indomethacin] explode all trees | 3160 | |
| #86 | MeSH descriptor: [Ibuprofen] explode all trees | 2525 | |
| #87 | (NSAID* or indomet?acin* or ibuprofen):ti,ab | 15750 | |
| #88 | MeSH descriptor: [Nandrolone] explode all trees | 338 | |
| #89 | MeSH descriptor: [Oxandrolone] explode all trees | 126 | |
| #90 | MeSH descriptor: [Testosterone Congeners] explode all trees | 4776 | |
| #91 | (androgen* or nandrolon* or oxandrol or enobosarm):ti,ab | 9069 | |
| #92 | MeSH descriptor: [Metoclopramide] explode all trees | 1350 | |
| #93 | (prokinetic* or metoclopramide):ti,ab | 3647 | |
| #94 | MeSH descriptor: [Mirtazapine] explode all trees | 383 | |
| #95 | mirtazapin*:ti,ab | 907 | |
| #96 | MeSH descriptor: [Olanzapine] explode all trees | 1602 | |
| #97 | olanzapin*:ti,ab | 3724 | |
| #98 | MeSH descriptor: [Hydrazines] explode all trees | 2403 | |
| #99 | hydrazin*:ti,ab | 60 | |
| #100 | MeSH descriptor: [Cyproheptadine] explode all trees | 732 | |
| #101 | cyproheptadin*:ti,ab | 214 | |
| #102 | MeSH descriptor: [Pentoxifylline] explode all trees | 730 | |
| #103 | pentoxifyllin*:ti,ab | 1381 | |
| #104 | MeSH descriptor: [Melatonin] explode all trees | 1757 | |
| #105 | melatonin*:ti,ab | 4195 | |
| #106 | MeSH descriptor: [Erythropoietin] explode all trees | 2618 | |
| #107 | erythropoetin*:ti,ab | 101 | |
| #108 | MeSH descriptor: [Eicosapentaenoic Acid] explode all trees | 1353 | |
| #109 | MeSH descriptor: [Fish Oils] explode all trees | 4622 | |
| #110 | MeSH descriptor: [Fatty Acids] explode all trees | 29124 | |
| #111 | (eicosapentaen* or docosahexaen* or "omega-3" or (fatty NEAR/1 acid*) or EPA or (oil* NEAR/6 (cod* or marin* or fish*)):ti,ab | 22606 | |
| #112 | MeSH descriptor: [Ghrelin] explode all trees | 890 | |
| #113 | ((ghrelin or ppghrelin or (motilin NEAR/2 peptide) or ghrl or obestatin or ppmtlrp or "appetite regulating hormone" or Anamorelin or Ipamorelin or Eganamorelin or Hexarelin or MK-677 or Rikkunshito)):ti,ab | 2562 | |
| #114 | anamorelin*:ti,ab | 74 | |
| #115 | MeSH descriptor: [Interferons] explode all trees | 7063 | |
| #116 | (interferon or INF):ti,ab | 17453 | |
| #117 | MeSH descriptor: [Thalidomide] explode all trees | 1055 | |
| #118 | thalidomid*:ti,ab | 1617 | |
| #119 | MeSH descriptor: [Etanercept] explode all trees | 996 | |
| #120 | etanercept:ti,ab | 2245 | |
| #121 | ponsegromab:ti,ab | 9 | |
| #122 | MeSH descriptor: [Antibodies, Monoclonal] explode all trees | 22059 | |
| #123 | infliximab:ti,ab | 2596 | |
| #124 | MeSH descriptor: [Carnitine] explode all trees | 811 | |
| #125 | carnitin*:ti,ab | 2051 | |
| #126 | MeSH descriptor: [Insulins] explode all trees | 18383 | |
| #127 | insulin:ti,ab | 58933 | |
| #128 | espidolol:ti,ab | 4 | |
| #129 | tocilizumab:ti,ab | 1737 | |
| #130 | MeSH descriptor: [Interleukin-6] explode all trees | 4348 | |
| #131 | {or #70-#130} | 266721 | |
| #132 | #69 and #131 | 2378 | |

EMBASE: 10-04-2025

| | |
|---|---------|
| #1. 'neoplasm'/exp | 6596867 |
| #2. 'cancer staging'/exp | 495857 |
| #3. cancer*:ti,ab | 3544858 |
| #4. tumor*:ti,ab | 2638609 |
| #5. tumour*:ti,ab | 465601 |
| #6. carcinoma*:ti,ab | 1129592 |
| #7. neoplasm*:ti,ab | 242363 |
| #8. lymphoma:ti,ab | 301286 |
| #9. melanoma:ti,ab | 206477 |
| #10. staging:ti,ab | 171263 |
| #11. metastas*:ti,ab | 698673 |
| #12. metastatic:ti,ab | 493453 |
| #13. 'metastasis'/exp | 910202 |
| #14. 'oncogenesis and malignant transformation'/exp | 1386284 |
| #15. neoplastic AND process*:ti,ab | 21722 |
| #16. (non NEAR/1 small NEAR/1 cell):ti,ab | 150986 |
| #17. adenocarcinoma*:ti,ab | 300375 |
| #18. (squamous NEAR/1 cell):ti,ab | 201172 |
| #19. nsclc:ti,ab | 125060 |
| #20. osteosarcoma*:ti,ab | 39979 |
| #21. phyllodes:ti,ab | 3426 |
| #22. cystosarcoma*:ti,ab | 697 |
| #23. fibroadenoma*:ti,ab | 6005 |
| #24. (nonsmall NEAR/2 cell):ti,ab | 127604 |
| #25. plasmacytoma*:ti,ab | 9524 |
| #26. myeloma:ti,ab | 111893 |
| #27. (multiple NEAR/1 myeloma):ti,ab | 89872 |
| #28. lymphoblastoma*:ti,ab | 356 |
| #29. lymphocytoma*:ti,ab | 463 |
| #30. lymphosarcoma*:ti,ab | 4613 |
| #31. immunocytoma:ti,ab | 472 |
| #32. sarcoma*:ti,ab | 152170 |
| #33. hodgkin*:ti,ab | 112995 |
| #34. nonhodgkin*:ti,ab OR ((non NEAR/1 hodgkin*):ti,ab) | 67939 |
| #35. malignan*:ti,ab | 1092803 |
| #36. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 | 7872986 |
| #37. 'heart failure'/exp | 744731 |
| #38. (heart NEAR/2 failure*):ab,ti | 396400 |
| #39. (myocardial NEAR/2 failure*):ab,ti | 6318 |

| | |
|---|---------|
| #40. (cardiac NEAR/2 failure*):ab,ti | 27148 |
| #41. (heart NEAR/2 decompensat*):ab,ti | 12495 |
| #42. #37 OR #38 OR #39 OR #40 OR #41 | 811654 |
| #43. 'chronic obstructive lung disease'/exp | 201140 |
| #44. emphysema*.ti,ab | 46254 |
| #45. (chronic* NEAR/3 bronchiti*):ti,ab | 16883 |
| #46. (obstruct* NEAR/3 (pulmonary OR lung* OR airway* OR airflow* OR bronch* OR respirat*)):ti,ab | 167109 |
| #47. copd:ti,ab OR coad:ti,ab OR cobd:ti,ab OR aecb:ti,ab | 123906 |
| #48. #43 OR #44 OR #45 OR #46 OR #47 | 324114 |
| #49. 'amyotrophic lateral sclerosis'/exp | 54294 |
| #50. 'motor neuron disease'/de | 15163 |
| #51. als:ti,ab | 49654 |
| #52. 'charcot disease':ti,ab | 49 |
| #53. 'lou gehrig':ti,ab | 273 |
| #54. #49 OR #50 OR #51 OR #52 OR #53 | 82963 |
| #55. #36 OR #42 OR #48 OR #54 | 8904168 |
| #56. 'anorexia'/exp | 78870 |
| #57. 'body weight loss'/exp | 264030 |
| #58. 'cachexia'/exp | 20126 |
| #59. 'malnutrition'/de | 87361 |
| #60. 'appetite'/exp | 30669 |
| #61. anorexi*.ti,ab | 58848 |
| #62. cachex*.ti,ab OR cachect*.ti,ab | 17899 |
| #63. malnourish*.ti,ab OR malnutrition:ti,ab OR emaciation:ti,ab OR 'weight loss':ti,ab OR underweight:ti,ab OR wasting:ti,ab OR wasted:ti,ab OR appetite:ti,ab OR starvation:ti,ab | 417250 |
| #64. #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 | 659110 |
| #65. 'progesterone derivative'/de | 3655 |
| #66. 'megestrol'/de | 1835 |
| #67. 'megestrol acetate'/de | 5826 |
| #68. 'medroxyprogesterone acetate'/de | 19725 |
| #69. megestrol*.ti,ab OR medroxyprogesteron*.ti,ab | 10455 |
| #70. 'corticosteroid'/de | 332892 |
| #71. corticosteroid*.ti,ab | 206694 |
| #72. 'dexamethasone'/de | 210911 |
| #73. 'dexamethasone derivative'/de | 167 |
| #74. 'prednisolone'/de | 168111 |
| #75. 'prednisolone derivative'/de | 170 |
| #76. 'prednisone'/de | 223052 |
| #77. 'methylprednisolone'/de | 135520 |
| #78. dexamethason*.ti,ab OR prednison*.ti,ab OR prednisolon*.ti,ab OR methylprednisolon*.ti,ab | 240937 |
| #79. 'cannabinoid'/de | 17779 |
| #80. 'cannabis'/de | 51630 |
| #81. 'dronabinol'/de | 10519 |

| | |
|--|--------|
| #82. cannabi*:ti,ab OR dronabinol:ti,ab OR thc:ti,ab OR tetrahydrocannabinol:ti,ab | 79304 |
| #83. 'nonsteroid antiinflammatory agent'/de | 156 |
| #84. 'indometacin'/de | 85951 |
| #85. 'ibuprofen'/de | 65384 |
| #86. nsaid*:ti,ab OR indomet?acin*:ti,ab OR ibuprofen:ti,ab | 117438 |
| #87. 'nandrolone'/de | 3153 |
| #88. 'oxandrolone'/de | 2009 |
| #89. 'testosterone derivative'/de | 1407 |
| #90. androgen*:ti,ab OR nandrolon*:ti,ab OR oxandrol:ti,ab OR enobosarm:ti,ab | 133616 |
| #91. 'metoclopramide'/de | 29382 |
| #92. 'prokinetic agent'/de | 4233 |
| #93. prokinetic*:ti,ab OR metoclopramide:ti,ab | 13928 |
| #94. 'mirtazapine'/de | 17 |
| #95. mirtazapin*:ti,ab | 4434 |
| #96. 'olanzapine'/de | 43571 |
| #97. olanzapin*:ti,ab | 16658 |
| #98. 'hydrazine derivative'/exp | 87753 |
| #99. hydrazin*:ti,ab | 16147 |
| #100.'cyproheptadine'/de | 9011 |
| #101.cyproheptadin*:ti,ab | 3177 |
| #102.'pentoxifylline'/de | 15655 |
| #103.pentoxifyllin*:ti,ab | 6518 |
| #104.'melatonin'/de | 47449 |
| #105.melatonin*:ti,ab | 40115 |
| #106.'erythropoietin'/de | 43447 |
| #107.'recombinant erythropoietin'/de | 25011 |
| #108.erythropoetin*:ti,ab OR epo:ti,ab | 19363 |
| #109.'icosapentaenoic acid'/de | 22287 |
| #110.'fish oil'/de | 20581 |
| #111.'fatty acid'/exp | 823168 |
| #112.eicosapentaen*:ti,ab OR docosahexaen*:ti,ab OR 'omega-3':ti,ab OR ((fatty NEAR/1 acid*):ti,ab) OR epa:ti,ab OR ((oil* NEAR/6 (cod* OR marin* OR fish*)):ti,ab) | 373308 |
| #113.'ghrelin'/exp | 19684 |
| #114.ghrelin:ti,ab OR ppghrelin:ti,ab OR ((motilin NEAR/2 peptide):ti,ab) OR ghrl:ti,ab OR obestatin:ti,ab OR ppmtlrp:ti,ab OR 'appetite regulating hormone':ti,ab OR anamorelin:ti,ab OR ipamorelin:ti,ab OR eganamorelin:ti,ab OR hexarelin:ti,ab OR 'mk 677':ti,ab OR rikkunshito:ti,ab | 17976 |
| #115.anamorelin*:ti,ab | 227 |
| #116.'anamorelin'/de | 377 |
| #117.'interferon'/de | 96590 |
| #118.interferon:ti,ab OR inf:ti,ab | 271525 |
| #119.'thalidomide'/de | 34247 |
| #120.thalidomid*:ti,ab | 15579 |
| #121.'etanercept'/de | 40368 |
| #122.etanercept:ti,ab | 17708 |

| | |
|--|---------|
| #123.ponsegromab:ti,ab | 18 |
| #124.'ponsegromab'/de | 30 |
| #125.'monoclonal antibody'/de | 240930 |
| #126.infliximab:ti,ab | 34262 |
| #127.'carnitine'/de | 21452 |
| #128.carnitin*:ti,ab | 24980 |
| #129.'insulin'/de | 424008 |
| #130.insulin:ti,ab | 592907 |
| #131.'espindolol'/de | 32 |
| #132.espindolol:ti,ab | 15 |
| #133.'tocilizumab'/de | 32164 |
| #134.tocilizumab:ti,ab | 15326 |
| #135.'interleukin 6'/de | 384702 |
| #136.il6:ti,ab | 251299 |
| #137.#65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87 OR #88 OR #89 OR #90 OR #91 OR #92 OR #93 OR #94 OR #95 OR #96 OR #97 OR #98 OR #99 OR #100 OR #101 OR #102 OR #103 OR #104 OR #105 OR #106 OR #107 OR #108 OR #109 OR #110 OR #111 OR #112 OR #113 OR #114 OR #115 OR #116 OR #117 OR #118 OR #119 OR #120 OR #121 OR #122 OR #123 OR #124 OR #125 OR #126 OR #127 OR #128 OR #129 OR #130 OR #131 OR #132 OR #133 OR #134 OR #135 OR #136 | 4099318 |
| #138.#55 AND #64 AND #137 | 44957 |
| #139.#55 AND #64 AND #137 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) AND ([article]/lim OR [article in press]/lim OR [review]/lim) AND ([dutch]/lim OR [english]/lim) AND [embase]/lim | 2547 |

Tabel 16. Resultaten van zoekactie van onderzoeksvraag 3

| Database | Aantal |
|--|-------------|
| Medline | 3765 |
| PreMedline | 35 |
| CDSR | 90 |
| CENTRAL | 2340 |
| Embase | 2547 |
| Totaal aantal resultaten | 8777 |
| Aantal geëxcludeerd (dubbelen, foute taal) | 1873 |
| Totaal aantal unieke resultaten | 6904 |

Tabel 17. Overzicht van geëxcludeerde studies gebaseerd op beoordeling van de volledige tekst van onderzoeksvraag 3

| Referentie | Reden voor exclusie |
|--|---------------------|
| Abernethy, A., et al. Anamorelin for the treatment of cancer anorexia-cachexia: baseline characteristics from three phase III clinical trials (the ROMANA program). Journal of clinical oncology, 2014. 32. | Abstract |
| Abernethy, A., et al. Phase III clinical trials with anamorelin HCL, a novel ghrelin receptor agonist for the treatment of NSCLC cachexia. Supportive care in cancer, 2013. 21, S144 DOI: 10.1007/s00520-013-1798-3. | Abstract |

| Referentie | Reden voor exclusie |
|---|---|
| Abernethy, A., et al. Results from romana 1 and 2: two phase III trials of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. Supportive care in cancer, 2015. 23, S43-s44 DOI: 10.1007/s00520-015-2712-y. | Abstract |
| Aliyazicioglu, T., et al., Effects of Standard and/or Glutamine Dipeptide and/or Omega-3 Fatty Acid-Supplemented Parenteral Nutrition on Neutrophil Functions, Interleukin-8 Level and Length of Stay--a Double Blind, Controlled, Randomised Study. East African Medical Journal, 2013. 90(2): p. 59-66. | Geen palliatieve patiënten, foute uitkomsten |
| Aredes, M.A., et al., Efficacy of ω -3 supplementation on nutritional status, skeletal muscle, and chemoradiotherapy toxicity in cervical cancer patients: A randomized, triple-blind, clinical trial conducted in a middle-income country. Nutrition, 2019. 67-68. | Curatieve chemoradiotherapie |
| Arrieta, O., et al. MA14.03 Effect of Mirtazapine on Energy Intake in Patients with Anorexia Associated with NSCLC. Journal of thoracic oncology, 2022. 17, S93 DOI: 10.1016/j.jtho.2022.07.155. | Abstract |
| Arvia, G., et al., Treatment of cancer cachexia in the very advanced or terminal phase: A systematic review. Italian Journal of Medicine, 2013. 7(4): p. 253-258. | Enkel PubMed |
| Baldi, S., et al., Fat-free mass change after nutritional rehabilitation in weight losing COPD: role of insulin, C-reactive protein and tissue hypoxia. International Journal of Copd, 2010. 5: p. 29-39. | Geen interventie uit de PICO |
| Barber MD, Ross JA, Preston T, et al. Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. J Nutr 1999;129:1120e1125 | Geen RCT |
| Beadle, J., et al. Survival and Quality of Life Data from the Act One Randomised, Double-Blind, Placebo-Controlled, Phase II Study of Espindolol for the Treatment and Prevention of Cachexia in Patients with Stage III / IV Non-Small Cell Lung Cancer or Colorectal Cancer. Annals of oncology, 2014. 25, iv162 DOI: 10.1093/annonc/mdu331.47. | Abstract |
| Berenstein, E.G. and Z. Ortiz, Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews, 2005(2): p. CD004310. | Updated |
| Berk, L., et al., A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Supportive Care in Cancer, 2008. 16(10): p. 1179-88. | Geen interventie uit de PICO |
| Bilbao, A. and R. Spanagel, Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Medicine, 2022. 20(1): p. 259. | Geen resultaten apart per aandoening |
| Bonomi, P., et al. Anamorelin for the treatment of cancer anorexia-cachexia in advanced NSCLC patients: results from Romana 1, a pivotal phase 3 study supportive care/palliation/nursing. International journal of radiation oncology biology physics, 2014. 90, S3. | Abstract |
| Brown, L.R., et al., Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series. Journal of Cachexia, Sarcopenia and Muscle, 2024. 15(3): p. 816-852. | Geen kwantitatieve rapportering van uitkomsten |
| Bruera, E., et al. A double-blind trial of megestrol acetate on appetite, caloric intake, nutritional status and other symptoms in patients with advanced cancer. Proceedings of the american society of clinical oncology, 1989. 8, 327, Abstract 1273. | Abstract |
| Bruera, E., et al., A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. Journal of Pain & Symptom Management, 2000. 19(6): p. 427-35. | Gaat niet primair om patiënten met anorexie en/of gewichtsverlies |

| Referentie | Reden voor exclusie |
|--|---|
| Bruera, E., et al., Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. <i>Journal of Pain & Symptom Management</i> , 2004. 28(4): p. 381-8. | Gaat primair om patiënten met misselijkheid |
| Bruera, E., et al., Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. <i>Cancer Prevention & Control</i> , 1998. 2(2): p. 74-8. | Geen full-text |
| Calder, P., et al. Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease (COPD): a randomized, double-blind controlled trial. <i>Journal of cachexia, sarcopenia and muscle</i> , 2017. 8, 174 DOI: 10.1002/jcsm.12182. | Abstract |
| Calder, P.C., et al., Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018. 9(1): p. 28-40. | Ongeveer 50% severe COPD |
| Canada, T. Effect of Fish Oil on Appetite and Other Symptoms in Patients with Advanced Cancer and Anorexia/Cachexia: a Double-Blind, Placebo-Controlled Study. <i>Nutrition in clinical practice</i> , 2003. 18, 524 DOI: 10.1177/0115426503018006524. | Abstract |
| Capitao, C., et al., Protein intake and muscle mass maintenance in patients with cancer types with high prevalence of sarcopenia: a systematic review. <i>Supportive Care in Cancer</i> , 2022. 30(4): p. 3007-3015. | Geen interventie uit de PICO |
| Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. <i>Am J Respir Crit Care Med</i> . 2004;170:870–8 | Stable COPD |
| Cerchietti, L.C.A., A.H. Navigante, and M.A. Castro, Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. <i>Nutrition and Cancer</i> , 2007. 59(1): p. 14-20. | Foute populatie |
| Cerny, T., et al. Oral cannabis - extract (CE) versus delta-9-tetrahydrocannabinol (THC) for patients with cancer-related anorexia (CRA): a randomized, double-blind, placebo-controlled study. <i>Proceedings of the american society of clinical oncology</i> , 2003. 730. | Abstract |
| Chao, Y.; Chan,W.K.;Wang, S.S.; Lai, K.H.; Chi, C.W.; Lin, C.Y.; Chan, A.; Whang-Peng, J.; Lui,W.Y.; Lee, S.D. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. <i>J. Gastroenterol. Hepatol</i> . 1997, 12, 277–281 | Geen RCT |
| Childs, D.S. and A. Jatoi, A hunger for hunger: a review of palliative therapies for cancer-associated anorexia. <i>Annals of Palliative Medicine</i> , 2019. 8(1): p. 50-58. | Narrative review |
| Chlebowski, R., et al. Influence of hydrazine sulfate on carbohydrate metabolism in cancer cachexia: a randomized, placebo controlled trial. <i>Proceedings of the american society of clinical oncology</i> , 1982. 1, 59, Abstract C-229. | Abstract |
| Chlebowski, R.T., et al., Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss. <i>Cancer Research</i> , 1984. 44(2): p. 857-61. | Effect op gewicht slechts beperkt gerapporteerd |
| Chow, P.K.H., et al., Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2011. 105(7): p. 945-952. | Bedoeld als antineoplastische behandeling |
| Chowdhury, I.H., et al., Mirtazapine versus megestrol acetate in treatment of anorexia-cachexia in advanced cancer patients: a randomized, double-blind trial. <i>Japanese Journal of Clinical Oncology</i> , 2024. 54(5): p. 530-536. | 30% st. IV |
| Christopher, C.D., et al. Treating anorexia in people with advanced cancer. a randomised, double blind, controlled trial of megestrol acetate, dexamethasone or | Abstract |

| Referentie | Reden voor exclusie |
|---|---------------------|
| placebo. Journal of clinical oncology, 2018. 36, DOI: 10.1200/JCO.2018.36.15-suppl.10020. | |
| Collichio, F.A.; Pandya, K. Interferon alpha-2b and megestrol acetate in the treatment of advanced renal cell carcinoma: A phase II study. Am J Clin Oncol. 1998, 21, 209–211 | Geen RCT |
| Correia Filho, R.C., et al., Nutritional and pharmacological approaches to cancer cachexia: a systematic review. International Journal of Nutrology, 2024. 17(1). | Narrative review |
| Crawford, J., et al. Enobosarm and lean body mass in patients with non-small cell lung cancer. Journal of clinical oncology, 2014. 32. | Abstract |
| Crawford, J., et al. Enobosarm, a selective androgen receptor modulator (SARM), increases lean body mass (LBM) in advanced nscL patients; updated results of two pivotal, international phase 3 trials. Supportive care in cancer, 2014. 22, S30-s31 DOI: 10.1007/s00520-014-2222-3. | Geen full-text |
| Crawford, J., et al. LBA82 Efficacy and safety of ponesimab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: a randomized, placebo-controlled, phase II study. Annals of oncology, 2024. 35, S1269 DOI: 10.1016/j.annonc.2024.08.2325. | Abstract |
| Crawford, J., et al. Randomized trials in nscL investigating the selective androgen receptor modulator (SARM) enobosarm to prevent and treat muscle wasting: feasibility and characteristics of patients at baseline. Supportive care in cancer, 2013. 21, S268 DOI: 10.1007/s00520-013-1798-3. | Geen full-text |
| Crawford, J., et al. Results from two Phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in NSCLC. European journal of cancer, 2013. 49, S10 DOI: 10.1016/S0959-8049(13)70070-4. | Geen full-text |
| Crawford, J., et al. Results from two phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in NSCLC. Journal of thoracic oncology, 2013. 8, S1199 DOI: 10.1097/01.JTO.0000438438.14562.c8. | Abstract |
| Creutzberg, E., et al. Effects of infliximab on systemic features in patients with COPD suffering from cachexia. European respiratory journal, 2006. 28, 105s [E689]. | Geen full-text |
| Croot, C., et al. Effect of enobosarm, a selective androgen receptor modulator, in non-small cell lung cancer (NSCLC) patients with muscle wasting in a phase IIB trial. Lung cancer (Amsterdam, Netherlands), 2013. 80, S32. | Abstract |
| Currow, D. and J. Temel Anamorelin HCL for the treatment of anorexia-cachexia in NSCLC: baseline characteristics of patients in the phase III clinical trial Romana 2 (HT-ANAM-302). Journal of thoracic oncology, 2013. 8, S1314 DOI: 10.1097/01.JTO.0000438438.14562.c8. | Abstract |
| Currow, D. and P. Bonomi The effect of anamorelin on body composition of patients with advanced non-small cell lung cancer (NSCLC) and anorexia/cachexia: pooled analysis of two phase 3 trials. Supportive care in cancer, 2019. 27, S187-s188 DOI: 10.1007/s00520-019-04813-1. | Abstract |
| Currow, D., et al. A safety extension study of anamorelin in advanced non-small cell lung cancer patients with cachexia: ROMANA 3. Journal of clinical oncology, 2015. 33. | Abstract |
| Currow, D., et al. Anamorelin in cachectic patients with advanced NSCLC, a Post-Hoc pooled efficacy data analysis of two phase 3 trials. Journal of thoracic oncology, 2017. 12, S665-s666. | Abstract |

| Referentie | Reden voor exclusie |
|---|---|
| Currow, D., et al. Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m ²): a pooled efficacy data analysis of two phase 3 studies. <i>Journal of clinical oncology</i> , 2016. 34. | Abstract |
| Currow, D., et al. Body weight response with anamorelin in advanced non-small cell lung cancer (NSCLC) patients with anorexia/cachexia: pooled analysis of two phase III trials. <i>Journal of clinical oncology</i> , 2017. 35. | Abstract |
| Currow, D., et al. LBA95 Anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia: efficacy and safety in the multinational phase III SCALA program. <i>Annals of oncology</i> , 2023. 34, S1335 DOI: 10.1016/j.annonc.2023.10.098. | Abstract |
| Currow, D., et al. Pooled analysis of two phase 3 trials: body weight response with anamorelin in advanced non-small cell lung cancer (nsclc) patients with anorexia/cachexia. <i>Supportive care in cancer</i> , 2017. 25, S189 DOI: 10.1007/s00520-017-3704-x. | Abstract |
| Currow, D., et al. Pooled efficacy data from romana 1 and romana 2, two phase 3 trials of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. <i>Supportive care in cancer</i> , 2016. 24, S23-s24 DOI: 10.1007/s00520-016-3209-z. | Abstract |
| Currow, D., et al. Results from Romana 3: a safety extension study of anamorelin in advanced non-small cell lung cancer patients with cachexia. <i>Supportive care in cancer</i> , 2015. 23, S44 DOI: 10.1007/s00520-015-2712-y. | Abstract |
| Currow, D., et al. ROMANA 3: a safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. <i>European journal of cancer</i> , 2015. 51, S239. | Abstract |
| Currow, D., et al. Treating anorexia in people with advanced cancer. A randomised, double blind, controlled trial of megestrol acetate, dexamethasone or placebo. <i>Supportive care in cancer</i> , 2018. 26, S198 DOI: 10.1007/s00520-018-4193-2. | Abstract |
| Currow, D., et al., Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and acute phase protein reaction (APPR): Pooled analysis of two phase 3 trials (ROMANA 1 and ROMANA 2). <i>Annals of Oncology</i> , 2016. 27: p. vi501. | Abstract |
| Daga, M.K., et al., Study of body composition, lung function, and quality of life following use of anabolic steroids in patients with chronic obstructive pulmonary disease. <i>Nutrition in Clinical Practice</i> , 2014. 29(2): p. 238-45. | Onduidelijk hoeveel palliatieve patiënten |
| Darnton, S.J., et al., The use of an anabolic steroid (nandrolone decanoate) to improve nutritional status after esophageal resection for carcinoma. <i>Diseases of the Esophagus</i> , 1999. 12(4): p. 283-8. | Chirurgisch behandelde patiënten |
| Del, F.E., et al. The effect of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebocontrolled trial. <i>Supportive care in cancer</i> , 2012. 20, S247 DOI: 10.1007/s00520-012-1479-7. | Abstract |
| Dentener, M.A., et al., Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: A pilot study. <i>Respiration</i> , 2008. 76(3): p. 275-282. | Onduidelijk hoeveel palliatieve patiënten |
| Dobs, A.S., et al., Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. <i>Lancet Oncology</i> , 2013. 14(4): p. 335-45. | Onduidelijk hoeveel palliatieve patiënten |
| Dodson, S., et al. Effect of enobosarm on overall survival in a phase iib study in NSCLC patients with >8% weight loss. <i>Journal of thoracic oncology</i> , 2012. 7, S68-s69 DOI: 10.1097/JTO.0b013e318253d2ff. | Abstract |

| Referentie | Reden voor exclusie |
|---|-------------------------------|
| Dodson, S., et al. Effect of enobosarm on physical function in cancer patients with <5 % or ≥5 % weight loss in a phase IIb trial. Supportive care in cancer, 2012. 20, S131-s132 DOI: 10.1007/s00520-012-1479-7. | Abstract |
| Dodson, S., et al. Effect of enobosarm, a selective androgen receptor modulator, on physical function in NSCLC patients with muscle wasting. Journal of thoracic oncology, 2012. 7, S69 DOI: 10.1097/JTO.0b013e318253d2ff. | Abstract |
| Dodson, S., et al. Enobosarm improves physical function in cancer patients with < or ≥ 5% weight loss in a phase IIb trial. Journal of thoracic oncology, 2012. 7, S149. | Abstract |
| Dodson, S., et al. GTX-024, a selective androgen receptor modulator (SARM), improves physical function in non-small cell lung cancer (NSCLC) patients with cancer cachexia. Journal of thoracic oncology, 2011. 6, S308-s309. | Abstract |
| Dodson, S., et al. In a phase IIb trial in cancer patients with muscle wasting, enobosarm improves physical function in both hypogonadal and eugonadal subjects. Journal of thoracic oncology, 2012. 7, S149. | Abstract |
| Dos Santos MR, Sayegh ALC, Bacurau AVN, Arap MA, Brum PC, Pereira RMR, et al. Effect of Exercise Training and Testosterone Replacement on Skeletal Muscle Wasting in Patients With Heart Failure With Testosterone Deficiency. Mayo Clin Proc. 2016;91:575–86 | Geen interventie uit de PICO |
| Downer, S., et al., A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. British Journal of Cancer, 1993. 67(5): p. 1102-5. | Dubbel |
| Engelen, M.P.K.J.; Safar, A.M.; Bartter, T.; Koeman, F.; Deutz, N.E.P. High anabolic potential of essential amino acid mixtures in advanced non-small cell lung cancer. Ann. Oncol. 2015, 26, 1960–1966 | Geen interventie uit de PICO |
| Falqueto, H., et al., Can conditions of skeletal muscle loss be improved by combining exercise with anabolic–androgenic steroids? A systematic review and meta-analysis of testosterone-based interventions. Reviews in Endocrine and Metabolic Disorders, 2021. 22(2): p. 161-178. | Sarcopenie = primair eindpunt |
| Fearon, K., et al. An energy and protein dense, high n-3 fatty acid oral supplement promotes weight gain in cancer cachexia. European journal of cancer, 2001. 37, 27 Abs. 90. | Abstract |
| Fearon, K., et al. Body composition in non-small cell lung cancer (NSCLC) patients with cachexia and improved anorexia-cachexia symptoms: anamorelin phase 3 trials pooled analysis. Clinical nutrition (Edinburgh, Scotland), 2016. 35, S18-s19. | Abstract |
| Ferreira, I.M., et al., The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest, 1998. 114(1): p. 19-28. | Stable COPD |
| Fisher, G. A phase III study of xilonix in refractory colorectal cancer patients with weight loss. Journal of clinical oncology, 2015. 33. | Abstract |
| Fonseca, G. and S. von Haehling, An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia. Expert Opinion on Pharmacotherapy, 2021. 22(7): p. 889-895. | Narrative review |
| Garcia, J., et al. Analysis of body composition parameters in patients from romana 1 and 2: phase III studies of anamorelin in nsclc patients with cachexia. Endocrine reviews, 2015. 36. | Abstract |
| Garcia, J.M. and T.A. Shamliyan, Nonsteroidal Anti-Inflammatory Drugs in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. American Journal of Medicine, 2017. 130(9): p. 1033-1036. | Geen systematische review |

| Referentie | Reden voor exclusie |
|--|---|
| Gebbia, V., A. Testa, and N. Gebbia, Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. <i>British Journal of Cancer</i> , 1996. 73(12): p. 1576-80. | Vergelijking van dosissen |
| Gertner, J. and B. Levinson SUN11031 (synthetic human ghrelin) improves lean body mass (LBM) and function in advanced COPD cachexia. European respiratory society annual congress, barcelona, spain, september 18-22, 2010. [e2154]. | Abstract |
| Giacomin AS, Sergio A, Vanin V, Tartaro P, Paccagnella D, Mazzucco M, Farinati F. Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era. <i>Hepato Res</i> 2010; 40: 153-160 | Bedoeld als antineoplastische behandeling |
| Giacosa, A., et al., Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. <i>Rivista Italiana di Nutrizione Parenterale ed Enterale</i> , 1997. 15(1): p. 20-23. | Geen full-text |
| Goldberg, R.M., et al. A randomized, placebo-controlled evaluation of pentoxifylline (PEN) in patients (pts) with cancer anorexia and cachexia (CAC): a North Central Treatment Group Study. <i>Proceedings of the american society of clinical oncology</i> , 1994. 13, 459, Abstract 1592. | Abstract |
| Goldberg, R.M., et al., Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Oncology</i> , 1995. 13(11): p. 2856-9. | Abstract |
| Gómez-Candela, C., et al. Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients. <i>Nutricion hospitalaria</i> , 2011. 26, 1385-1393 DOI: 10.1590/S0212-16112011000600028. | Spaans |
| Gonzalez, B.M., et al. Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. <i>Annals of oncology</i> , 1990. 1, 29-31. | Geen full-text |
| Guarcello M, Riso S, Buosi R, D'Andrea F. EPA-enriched oral nutritional support in patients with lung cancer: effects on nutritional status and quality of life. <i>Nutr Ther Metabol</i> 2007;25(1):25-30 | Geen full-text |
| Guo, Y.F.; Jiao, Z.M. Clinical study on treatment of advanced non-small cell lung cancer by arsenious acid combined with Ta-1 thymus peptide and megestrol acetate. <i>Chin. J. Integr. Tradit. West. Med.</i> 2002, 8, 262–266 | Combinatie niet relevant volgens PICO |
| Harilal, V., H. Kumar, and S. Beniwal Prednisolone Therapy As An Intervention In Terminal Cancer Patients, A Prospective Randomized Double Blind Cross Over Study. <i>Journal of cancer research and therapeutics</i> , 2017. 13, S16. | Abstract |
| Hariyanto, T.I. and A. Kurniawan, Cachexia in cancer patients: Systematic literature review. <i>Asian Journal of Oncology</i> , 2020. 6(3): p. 107-115. | Geen full-text |
| Hauser, W., et al., Cannabinoids in Pain Management and Palliative Medicine. <i>Deutsches Arzteblatt International</i> , 2017. 114(38): p. 627-634. | Focus op pijnbehandeling |
| Heckmayr, M. and U. Gatzemeier, Treatment of cancer weight loss in patients with advanced lung cancer. <i>Oncology</i> , 1992. 49 Suppl 2: p. 32-4. | Geen full-text |
| Herodes, M., et al., Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2023. 14(2): p. 835-846. | Geen interventie uit de PICO |
| Herrejon A, Palop J, Inchaurraga I, Lopez A, Banuls C, Hernandez A, et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. <i>Med Clin Barc</i> 2011;137:193–198 | Geen full-text |

| Referentie | Reden voor exclusie |
|---|----------------------------------|
| Herrejon, A., et al. Effect Of 8-week 320 Mg Megestrol acetate Daily Administration In Severe COPD And Weight Loss. American journal of respiratory and critical care medicine, 2010. 181, A4484. | Abstract |
| Huang, W.J. and C.Y. Ko, Systematic review and meta-analysis of nutrient supplements for treating sarcopenia in people with chronic obstructive pulmonary disease. Aging Clinical and Experimental Research, 2024. 36(1). | Focus op sarcopenie |
| Hunter, C., et al. Mirtazapine in cancer-associated anorexia cachexia: a randomised, double-blind, placebo-controlled trial. Annals of oncology, 2019. 30, v923 DOI: 10.1093/annonc/mdz394.084. | Abstract |
| Inoue A, Yamada Y, Matsumura Y, et al: Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11:528-532, 2003 | Foute populatie |
| Izumi, K., et al., Androgen replacement therapy for cancer-related symptoms in male: result of prospective randomized trial (ARTFORM study). Journal of Cachexia, Sarcopenia and Muscle, 2021. 12(4): p. 831-842. | Foute populatie |
| Jafari-Vayghan, H., et al. Impact of Melatonin and Branched-Chain Amino Acids Cosupplementation on Quality of Life, Fatigue, and Nutritional Status in Cachectic Heart Failure Patients: A Randomized Controlled Trial. American journal of lifestyle medicine, 2022. 16, 130-140 DOI: 10.1177/1559827619874044. | >50% NYHA II |
| Jantharapattana, K. and O. Orapipatpong, Efficacy of EPA-enriched supplement compared with standard formula on body weight changes in malnourished patients with head and neck cancer undergone surgery: a randomized study. Head & Neck, 2020. 42(2): p. 188-197. | Chirurgisch behandelde patiënten |
| Jatoi, A., et al. A placebo-controlled trial of etanercept, a tumor necrosis factor (TNF) inhibitor, in patients with the cancer anorexia/weight loss syndrome. North Central Cancer Treatment Group (NCCTG) trial N00C1 [abstract] 2007. Journal of clinical oncology : ASCO annual meeting proceedings, 2006. 24, 476. | Abstract |
| Jatoi, A., et al. An eicosapentanoic acid (EPA)-enriched supplement versus megestrol acetate (MA) versus both for patients with cancer-associated wasting. A collaborative effort from the North Central Cancer Treatment Group (NCCTG) and the National Cancer Institute of Canada. Proceedings of the american society of clinical oncology, 2003. 743. | Abstract |
| Jatoi, A., et al. Dronabinol versus megestrol acetate versus both for cancer-associated anorexia: a North Central Cancer Treatment Group study. Proceedings of the american society of clinical oncology, 2001. 20 (Pt 1), 388a, Abstract 1547. | Abstract |
| Kaasa, S., et al. Efficacy of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with anorexia/cachexia and modified Glasgow Prognostic Score (mGPS) of 2: pooled analysis of two phase 3 trials. Annals of oncology, 2017. 28, v498 DOI: 10.1093/annonc/mdx382.005. | Abstract |
| Kapoor, N., et al., A Prospective Randomized Controlled Trial to Study the Impact of a Nutrition-Sensitive Intervention on Adult Women with Cancer Cachexia Undergoing Palliative Care in India. Integrative Cancer Therapies, 2017. 16(1): p. 74-84. | Geen interventie uit de PICO |
| Kardinal, C.G., et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. A Mayo Clinic/North Central Cancer Treatment Group trial. Proceedings of the american society of clinical oncology, 1990. 9, 325, Abstract 1258. | Abstract |
| Kardinal, C.G., et al., A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer, 1990. 65(12): p. 2657-62. | Heterogene populatie |
| Khan, S., et al., A Systematic Review of Cost-Effectiveness Analyses Examining Treatments for Cachexia Syndrome. Nutrition and Cancer, 2024. 76(7): p. 584-595. | Review van CEA's |

| Referentie | Reden voor exclusie |
|---|--|
| Kim, B.-H., et al. Effect of multimodal intervention care on cachexia in patients with advanced cancer compared to conventional management (MIRACLE): an open-label, parallel, randomized, phase 2 trial. <i>Journal of clinical oncology</i> , 2023. 41, e24135 DOI: 10.1200/jco.2023.41.16_suppl.e24135. | Abstract |
| Kim, S.Y., et al., Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study. <i>Clinical Therapeutics</i> , 2021. 43(10): p. 1757-1772. | Foute populatie |
| Klek, S., et al., Enriched enteral nutrition may improve short-term survival in stage IV gastric cancer patients: A randomized, controlled trial. <i>Nutrition</i> , 2017. 36: p. 46-53. | Geen relevante interventie |
| Kornek, G.V., et al., Placebo-controlled trial of medroxy-progesterone acetate in gastrointestinal malignancies and cachexia. <i>Onkologie</i> , 1996. 19(2): p. 164-168. | Geen full-text |
| Kouchaki, B., et al., Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers. <i>Supportive Care in Cancer</i> , 2018. 26(7): p. 2479-2489. | Onduidelijk hoeveel palliatieve patiënten |
| Lai, V., et al., Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. <i>Head & Neck</i> , 2008. 30(1): p. 67-74. | Geen interventie uit de PICO |
| Lai, Y.L., F.M. Fang, and C.Y. Yeh, Management of anorexic patients in radiotherapy: a prospective randomized comparison of megestrol and prednisolone. <i>Journal of Pain & Symptom Management</i> , 1994. 9(4): p. 265-8. | Patiënten die radiotherapie ondergingen (niet noodzakelijk palliatief) |
| Latifzadeh, S. and V. Entezari Effect of megestrol acetate, cyproheptadine, and their combination on appetite, body weight and quality of life (QOL) in cancer patients: a double-blind placebo-controlled clinical trial. <i>Journal of clinical oncology : ASCO annual meeting proceedings</i> , 2004. 22, 760. | Abstract |
| Laviano A, Calder PC, Schols A, Lonqvist F, Bech M, Muscaritoli M. Safety and tolerability of targeted medical nutrition for cachexia in non-small-cell lung cancer: a randomized, double-blind, controlled pilot trial. <i>Nutr Cancer</i> 2020;72:439–50 | Geen palliatieve patiënten |
| Laviano, A., et al. Targeted medical nutrition for cachexia in NSCLC: a randomized, controlled trial. <i>Journal of cachexia, sarcopenia and muscle</i> , 2018. 9, 207-208 DOI: 10.1002/jcsm.12284. | Abstract |
| Levinson, B. and J. Gertner Randomized study of the efficacy and safety of SUN11031 (synthetic human ghrelin) in cachexia associated with chronic obstructive pulmonary disease. <i>e-SPEN journal</i> , 2012. 7, e171-e175 DOI: 10.1016/j.clnme.2012.07.004. | Onduidelijk hoeveel palliatieve patiënten |
| Levitan, N.; Dowlati, A.; Craffey, M.; Tahsildar, H.; MacKay, W.; McKenney, J.; Remick, S.C. A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: Results of a phase II trial. <i>Lung Cancer</i> 1998, 22, 227–234 | Geen RCT |
| Liu, Y., et al. A randomized pilot study of atractylenolide I on gastric cancer cachexia patients. <i>Evidence-based complementary and alternative medicine : eCAM</i> , 2008. 5, 337-344 DOI: 10.1093/ecam/nem031. | Geen interventie uit de PICO |
| Loprinzi, C., et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia. <i>ASCO annual meeting</i> , 1997. | Abstract |
| Loprinzi, C.L., et al., Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. <i>Journal of the National Cancer Institute</i> , 1990. 82(13): p. 1127-32. | Geen full-text |

| Referentie | Reden voor exclusie |
|--|------------------------------|
| Lundholm K , D aneryd P , K orner U , H yltander A , Bosaeus I . Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia . Int J Oncol 2004 ; 24 : 505 – 12 | Geen RCT |
| Lundholm, K., et al., Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function. Cancer, 2004. 100(9): p. 1967-77. | Geen interventie uit de PICO |
| Lyra, M.M.F., et al., Immunonutrition in head and neck cancer: Systematic review and meta-analysis of its clinical and nutritional effects. Clinical Nutrition ESPEN, 2021. 41: p. 30-41. | Geen palliatieve patiënten |
| Macbeth, F., A. Grgeor, and Cott A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung cancer (Amsterdam, Netherlands), 1994. 1 Suppl 1, 88. | Abstract |
| Maccio, A., et al., A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecologic Oncology, 2012. 124(3): p. 417-25. | Geen relevante vergelijking |
| Madeddu, C., et al. A randomized phase III clinical trial of a combined treatment with megestrol acetate+carnitine+celecoxib+antioxidants vs. Megestrol acetate alone for patients with cancer cachexia syndrome. Supportive care in cancer, 2012. 20, S57-s58 DOI: 10.1007/s00520-012-1479-7. | Abstract |
| Madeddu, C., et al. Randomised phase III clinical trial of a combined treatment with carnitine+celecoxib±megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Journal of cachexia, sarcopenia and muscle, 2011. 2, 258 DOI: 10.1007/s13539-011-0045-3. | Abstract |
| Madeddu, C., et al. Randomised phase iii clinical trial of combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer cachexia. Supportive care in cancer, 2011. 19, S113-s114 DOI: 10.1007/s00520-011-1184-y. | Abstract |
| Madeddu, C., et al. Randomized phase III clinical trial of two different arms of a combined treatment with carnitine plus celecoxib with or without megestrol acetate for patients with cancer-related anorexia/cachexia syndrome (CACS). Journal of clinical oncology, 2011. 29. | Abstract |
| Maeng, C., et al. Effect of multimodal intervention care on cachexia in patients with advanced cancer compared to conventional management (MIRACLE): an open-label, phase 2 trial. Journal of clinical oncology, 2021. 39, DOI: 10.1200/JCO.2021.39.15_suppl.TPS12134. | Abstract |
| Malik, J.S. and S. Yennurajalingam, Prokinetics and ghrelin for the management of cancer cachexia syndrome. Annals of Palliative Medicine, 2019. 8(1): p. 80-85. | Narrative review |
| Mantovani, G., et al., An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial. Supportive Cancer Therapy, 2007. 4(3): p. 163-167. | Studieprotocol |
| May, P.E., et al., Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. American Journal of Surgery, 2002. 183(4): p. 471-9. | Geen interventie uit de PICO |
| Mazzuca, F., et al. Effect of nutritional support with highly purified, whey proteins for malnutrition and sarcopenia in patients affected with stage IIIII colorectal or breast cancer: a blind, placebo controlled, randomized clinical trial. Journal of clinical oncology, 2018. 36, DOI: 10.1200/jco.2018.36.15_suppl.tps10129. | Abstract |

| Referentie | Reden voor exclusie |
|--|--|
| McDonald, J., et al., Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2023. 14(5): p. 1932-1948. | Foute uitkomsten |
| McLuskie, A., et al., Nutritional interventions in randomised clinical trials for people with incurable solid cancer: A systematic review. <i>Clinical Nutrition</i> , 2025. 44: p. 201-219. | Geen interventie uit de PICO |
| McQuellon, R.P., et al., Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. <i>International Journal of Radiation Oncology, Biology, Physics</i> , 2002. 52(5): p. 1180-5. | Patiënten die radiotherapie ondergingen (niet noodzakelijk palliatief) |
| Miki, K., et al. Effects of ghrelin administration in cachectic patients with COPD. European respiratory society annual congress, barcelona, spain, september 18-22, 2010. [1957]. | Abstract |
| Miki, K., et al., A phase II, open-label clinical trial on the combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary disease. <i>Journal of Physiological Sciences: JPS</i> , 2019. 69(6): p. 969-979. | Geen RCT |
| Miki, K., et al., Effects of ghrelin treatment on exercise capacity in underweight COPD patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment. <i>BMC Pulmonary Medicine</i> , 2013. 13: p. 37. | Onduidelijk hoeveel palliatieve patiënten |
| Milla, S.P., et al., Adherence and impact of an oral nutritional supplement enriched in leucine, EVOO, EPA and DHA, and beta-glucans on the coverage of energy and protein requirements in patients with cancer and malnutrition: Alisenoc study. <i>Nutrition</i> , 2024. 120: p. 112355. | Onduidelijk hoeveel palliatieve patiënten |
| Milne, A., et al. Protein and energy supplementation in elderly people at risk from malnutrition. <i>Cochrane Database of Systematic Reviews</i> , 2009. DOI: 10.1002/14651858.CD003288.pub3. | Geen interventie uit de PICO |
| Mocellin MC, Camargo CdQ, Fabre MEdS, Trindade EBSdM. Fish oil effects on quality of life, body weight and free fat mass change in gastrointestinal cancer patients undergoing chemotherapy: a triple blind, randomized clinical trial. <i>J Functional Foods</i> 2017;31:113-22 | Onduidelijk hoeveel palliatieve patiënten |
| Mocellin, M.C., et al., Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients. <i>Lipids</i> , 2013. 48(9): p. 879-88. | Geen palliatieve patiënten |
| Moertel CG, Schutt AJ, Reitemeier RJ, et al: Corticosteroid therapy of preterminal gastrointestinal cancer. <i>Cancer</i> 33:1607-1609, 1974 | Gewicht niet kwantitatief gerapporteerd |
| Moianu, A., G. Șerban, and S. Andone, The Role of Short-Chain Fatty Acids in Microbiota–Gut–Brain Cross-Talk with a Focus on Amyotrophic Lateral Sclerosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2023. 24(20). | Dubbel |
| Molfino, A., et al., Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2019. 28(8): p. 733-740. | Narrative review |
| Motataianu, A., G. Serban, and S. Andone, The Role of Short-Chain Fatty Acids in Microbiota-Gut-Brain Cross-Talk with a Focus on Amyotrophic Lateral Sclerosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2023. 24(20): p. 11. | Foute uitkomsten |
| Murphy RA, Mourtzakis M, Chu QS, et al. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. <i>Cancer</i> . 2011;117:1775-1782 | Onduidelijk hoeveel palliatieve patiënten |
| Navari, R. and M. Brenner Treatment of cancer related anorexia with olanzapine and megestrol acetate. <i>Supportive care in cancer</i> , 2009. 17(7), 971. | Abstract |

| Referentie | Reden voor exclusie |
|---|---|
| Navari, R. and M. Brenner Treatment of cancer-related anorexia with olanzapine and megestrol acetate. <i>Journal of clinical oncology</i> , 2008. 26(15 suppl), 9576. | Abstract |
| Navari, R.M. and M.C. Brenner, Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. <i>Supportive Care in Cancer</i> , 2010. 18(8): p. 951-6. | Onduidelijk hoeveel palliatieve patiënten |
| Nelson, K.A.;Walsh, D.; Hussein, M. A phase II study of low-dose megestrol acetate using twice-daily dosing for anorexia in nonhormonally dependent cancer. <i>Am. J. Hosp. Palliat. Care</i> 2002, 19, 206–210 | Geen RCT |
| Neri, B., V.L. Garosi, and C. Intini, Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. <i>Anti-Cancer Drugs</i> , 1997. 8(5): p. 459-65. | Onduidelijk hoeveel palliatieve patiënten |
| Nielsen, R.L., et al., The appetite stimulating effect and safety of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in older patients with poor appetite: A triple-blinded, randomized, placebo-controlled, cross-over trial. <i>Clinical Nutrition</i> , 2025. 47: p. 248-257. | Foute populatie |
| Niiranen, A., et al., The clinical effect of medroxyprogesterone (MPA) in elderly patients with lung cancer. <i>American Journal of Clinical Oncology</i> , 1990. 13(2): p. 113-6. | Onduidelijk hoeveel palliatieve patiënten |
| Ogasawara, T., et al., Effect of eicosapentaenoic acid on prevention of lean body mass depletion in patients with exacerbation of chronic obstructive pulmonary disease: A prospective randomized controlled trial. <i>Clinical Nutrition ESPEN</i> , 2018. 28: p. 67-73. | >50% GOLD I-II |
| Orea-Tejeda, A., et al., Effects of thalidomide treatment in heart failure patients. <i>Cardiology</i> , 2007. 108(4): p. 237-242. | >75% NYHA II |
| Orr, R. and M. Fiatarone Singh, The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. <i>Drugs</i> , 2004. 64(7): p. 725-50. | Narrative review |
| Orsso, C.E., et al., Effects of high-protein supplementation during cancer therapy: a systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2024. 120(6): p. 1311-1324. | Geen interventie uit de PICO |
| Osman, N., et al. 1294TiP Olanzapine for anorexia in cancer cachexia patients: a placebo-controlled randomized trial. <i>Annals of oncology</i> , 2022. 33, S1134 DOI: 10.1016/j.annonc.2022.07.1426. | Abstract |
| Ostwal, S. and J. Deodhar Role of megestrol acetate versus dexamethasone for improvement in appetite in patients with cancer associated anorexia cachexia: a randomized controlled pilot trial. <i>Journal of pain and symptom management</i> , 2017. 53, 439-440 DOI: 10.1016/j.jpainsymman.2016.12.265. | Abstract |
| Ostwal, S., et al. Role of megestrol acetate versus dexamethasone for improvement in appetite in patients with cancer associated anorexia cachexia: a randomized controlled pilot trial. <i>Annals of oncology</i> , 2018. 29, viii616 DOI: 10.1093/annonc/mdy300.042. | Abstract |
| Ostwal, S., et al. Role of megestrol acetate versus dexamethasone for improvement in appetite in patients with cancer associated anorexia cachexia: a randomized controlled pilot trial. <i>Supportive care in cancer</i> , 2018. 26, S209 DOI: 10.1007/s00520-018-4193-2. | Abstract |
| Pardo, J., A. Mena, and L. Montsech Megestrol acetate for anorexia in lung cancer patients undergoing radiation therapy. A randomized trial comparing the efficacy of two different doses in 130 patients. <i>Proceedings of the american society of clinical oncology</i> , 2003. 765. | Abstract |
| Pardo, J., A. Mena, and L. Montsech Megestrol acetate for anorexia in lung cancer patients undergoing radiation therapy: a randomized trial comparing the efficacy of two | Abstract |

| Referentie | Reden voor exclusie |
|---|---|
| different doses. Preliminary results in 99 patients. International journal of radiation oncology biology physics, 2001. 51, 343. | |
| Paulsen, O., et al. Do methylprednisolone 32 mg provide pain relief, improve fatigue and appetite in cancer patients using opioids? A randomized, controlled trial. European journal of cancer, 2013. 49, S270 DOI: 10.1016/S0959-8049(13)70061-3. | Abstract |
| Paulsen, O., et al., Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. Journal of Clinical Oncology, 2014. 32(29): p. 3221-8. | Statistiek lijkt enkel op primair doelgericht pijnbestrijding |
| Paval, D.R., et al., A systematic review examining the relationship between cytokines and cachexia in incurable cancer. Journal of Cachexia, Sarcopenia and Muscle, 2022. 13(2): p. 824-838. | Geen interventie-studies |
| Pawlowski GJ: Cyproheptadine: Weight gain and appetite stimulation in essential anorexic adults. Curr Ther Res Clin Exp 18:673-678, 1975 | Geen full-text |
| Popiela T, Lucchi R, Giongo F: Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 25: 1823-1829, 1989 | Onduidelijk hoeveel patiënten met anorexie |
| Prado, B.L. and Y. Qian, Anti-cytokines in the treatment of cancer cachexia. Annals of Palliative Medicine, 2019. 8(1): p. 67-79. | Narrative review |
| Pratt, V.C., et al., Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. British Journal of Cancer, 2002. 87(12): p. 1370-8. | Geen uitkomsten uit PICO |
| Reid, J., et al. Multimodal interventions for cachexia management. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD015749.pub2. | Geen interventie uit de PICO |
| Reutzberg, E., et al. Effects of infliximab on local and systemic inflammation in patients with COPD suffering from cachexia. European respiratory journal, 2006. 28, 105s [E690]. | Abstract |
| Riechelmann, R.P., et al., Phase II trial of mirtazapine for cancer-related cachexia and anorexia. American Journal of Hospice & Palliative Medicine, 2010. 27(2): p. 106-10. | Geen RCT |
| Ries, A., et al., A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliative Medicine, 2012. 26(4): p. 294-304. | Enkel PubMed |
| Robinson Jr, D.W., et al., The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. Journal of Supportive Oncology, 2008. 6(6): p. 283-290. | Geen full-text |
| Roca-Rodriguez MM, Garcia-Almeida JM, Lupianez-Perez Y, Rico JM, Toledo M, Alcaide-Torres J, et al. Effect of a specific supplement enriched with n-3 polyunsaturated fatty acids on markers of inflammation, oxidative stress and metabolic status of ear, nose and throat cancer patients. Oncol Rep 2014;31(1):405-14 | Behandeling met radiotherapie |
| Rolfe, M., et al., Pharmacological management of cardiac cachexia: a review of potential therapy options. Heart Failure Reviews, 2019. 24(5): p. 617-623. | Narrative review |
| Rozentryt, P., et al., The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: A randomized, double-blind pilot study. Journal of Cachexia, Sarcopenia and Muscle, 2010. 1(1): p. 35-42. | Geen interventie uit de PICO |
| Ruiz-García, V., et al., Megestrol acetate: A systematic review usefulness about the weight gain in neoplastic patients with cachexia. Medicina Clinica, 2002. 119(5): p. 166-170. | Geen full-text |
| Sanchetee, S. and S. Sanchetee Thalidomide versus thalidomide with Olanzapine & Megastrol acetate in treatment of cachexia in gastro intestinal cancer; a randomized trial. Supportive care in cancer, 2010. 18, S171 DOI: 10.1007/s00520-010-0891-0. | Abstract |

| Referentie | Reden voor exclusie |
|--|---|
| Sanchettee, S. Thalidomide in the treatment of cancer cachexia in gastrointestinal cancer: a randomised placebo controlled trial. <i>Annals of oncology</i> , 2009. 20, 97. | Geen full-text |
| Schmoll, E., et al. Placebo controlled study with megestrol-acetate (MA) in anorexia and cachexia in patients with advanced cancer. <i>Journal of cancer research and clinical oncology</i> , 1992. 118, R10. | Geen full-text |
| Schmoll, E., et al., Megestrol acetate in cancer cachexia. <i>Seminars in Oncology</i> , 1991. 18(1 Suppl 2): p. 32-4. | Geen full-text |
| Schmoll, E., Risks and benefits of various therapies for cancer anorexia. <i>Oncology</i> , 1992. 49 Suppl 2: p. 43-5. | Geen full-text |
| Schols, A.M.W.J., et al., Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: A placebo-controlled randomized trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995. 152(4 I): p. 1268-1274. | Geen full-text |
| Segui, M., et al. Double-blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate. <i>Proceedings of the american society of clinical oncology</i> , 1996. 15, 529. | Abstract |
| Shalev, I., et al. #1782591 Potential to Optimize Weight Loss with Enobosarm: augment Reduction of Fat Mass while Preserving Muscle in Older Patients with Obesity. <i>Endocrine practice</i> , 2024. 30, S65 DOI: 10.1016/j.eprac.2024.03.250. | Abstract |
| Shirai, Y.; Okugawa, Y.; Hishida, A.; Ogawa, A.; Okamoto, K.; Shintani, M.; Morimoto, Y.; Nishikawa, R.; Yokoe, T.; Tanaka, K.; et al. Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia. <i>Sci. Rep.</i> 2017, 7, 4826 | Geen RCT |
| Silva A, Trindade EB, Fabre ME, Menegotto VM, Gevaerd S, Buss Zda S, et al. Fish oil supplement alters markers of inflammatory and nutritional status in colorectal cancer patients. <i>Nutr Canc</i> 2012;64(2):267-73 | Geen palliatieve patiënten |
| Sim, E., et al., The Effect of Omega-3 Enriched Oral Nutrition Supplement on Nutritional Indices and Quality of Life in Gastrointestinal Cancer Patients: A Randomized Clinical Trial. <i>Asian Pacific Journal of Cancer Prevention: Apjcp</i> , 2022. 23(2): p. 485-494. | Onduidelijk hoeveel palliatieve patiënten |
| Singuluri, S., et al. 275MO Phase III double blind placebo-controlled study of olanzapine for chemotherapy related anorexia in patients with advanced gastric, hepatopancreaticobiliary and lung cancer. <i>Annals of oncology</i> , 2022. 33, S1540 DOI: 10.1016/j.annonc.2022.10.302. | Abstract |
| Slevin, M., et al. A randomized double blind placebo controlled trial of medroxyprogesterone acetate in cancer cachexia. <i>Proceedings of the american society of clinical oncology</i> , 1988. 7, 283, Abstract 1097. | Abstract |
| Solheim, T.S., et al., A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017. 8(5): p. 778-788. | Geen relevante interventie |
| Solís-Martínez O, Plasa-Carvalho V, Phillips-Sixtos G, Trujillo-Cabrera Y, Hernandez-Cuellar A, Queipo-García GE, et al. Effect of eicosapentaenoic acid on body composition and inflammation markers in patients with head and neck squamous cell cancer from a public hospital in Mexico. <i>Nutr Canc</i> 2018;70(4):663-70 | Geen palliatieve patiënten |
| Sousa, M.S., et al., Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial). <i>PLoS ONE [Electronic Resource]</i> , 2023. 18(5): p. e0285850. | Studieprotocol |

| Referentie | Reden voor exclusie |
|--|------------------------------------|
| Steiner, M., et al. Effect of GTx-024, a selective androgen receptor modulator (SARM), on physical function in patients with non-small cell lung cancer (NSCLC) with cancer cachexia. <i>Journal of clinical oncology</i> , 2011. 29. | Abstract |
| Stout M, Tew GA, Doll H, Zwierska I, Woodrooffe N, Channer KS, et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. <i>Am Heart J</i> . 2012;164:893–901 | Geen interventie uit de PICO |
| Strasser, F., et al. Intravenous ghrelin for cancer-related anorexia/cachexia: a randomized, placebo-controlled, double-blind, double cross-over phase I/II study [abstract] 2018. <i>Journal of clinical oncology : ASCO annual meeting proceedings</i> , 2006. 24, 497. | Abstract |
| Szefel, J., et al., L-carnitine and cancer cachexia. I. L-carnitine distribution and metabolic disorders in cancer cachexia. <i>Oncology Reports</i> , 2012. 28(1): p. 319-23. | Geen interventie uit de PICO |
| Szlendak, M. and A. Kapala, Does the ratio of eicosapentaenoic acid to docosahexaenoic acid matter in cancer treatment? A systematic review of their effects on cachexia-related inflammation. <i>Nutrition</i> , 2024. 124: p. 112466. | Enkel PubMed |
| Takayama, K., et al., Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study. <i>Cancer Medicine</i> , 2023. 12(3): p. 2918-2928. | Post-hoc analyse van Takayama 2016 |
| Talbot, D., et al. A randomised double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. <i>British journal of cancer</i> , 1988. 58, 267. | Geen full-text |
| Temel, J., et al. Anamorelin for the Treatment of Cancer Anorexia-Cachexia in Nscl: results from the Phase 3 Studies Romana 1 and 2. <i>Annals of oncology</i> , 2014. 25, v1 DOI: 10.1093/annonc/mdu438.62. | Abstract |
| Temel, J., et al. Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m ²): post-hoc analysis of two phase III studies. David Christopher Currow. <i>Journal of clinical oncology</i> , 2016. 34, 203 DOI: 10.1200/jco.2016.34.26-suppl.203. | Abstract |
| Temel, J., et al. Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients. <i>Journal of clinical oncology</i> , 2013. 31. | Abstract |
| Temel, J., et al. Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2). <i>Journal of clinical oncology</i> , 2015. 33. | Abstract |
| Tominaga, T., et al., Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. <i>European Journal of Cancer Part A: General Topics</i> , 1994. 30(7): p. 959-964. | Gaat over antitumorale effecten |
| Tuna, T. and G. Samur, The Role of Nutrition and Nutritional Supplements in the Prevention and Treatment of Malnutrition in Chronic Obstructive Pulmonary Disease: Current Approaches in Nutrition Therapy. <i>Current Nutrition Reports</i> , 2025. 14(1): p. 21. | Narrative review |
| Turcott J, Guillen- Núñez MDR, Flores D, Oñate L, Zatarain-Barrón Z, Barrón F, et al. MA02.08 The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. <i>J Thorac Oncol</i> . 2018;13(10):S360–1 | Abstract |
| Turcott, J., et al. Effect Of Mirtazapine On Energy Intake In Patients With Anorexia Associated With Non-Small Cell Lung Cancer. <i>Clinical nutrition ESPEN</i> , 2023. 54, 470-471 DOI: 10.1016/j.clnesp.2022.09.048. | Abstract |

| Referentie | Reden voor exclusie |
|---|---|
| Uchino J., N. Katakami, T. Yokoyama, T. Naito, M. Kondo, K. Eguchi, ONO-7643/anamorelin for the treatment of patients with non-small cell lung cancer and cachexia: results from phase 2 study with Japanese patients, ESMO, Ann Oncol . 27 (6) (2016) 497–521 | Abstract |
| Uchino, J., et al. ONO-7643/anamorelin for the treatment of patients with non-small cell lung cancer and cachexia: results from phase 2 study with Japanese patients. Annals of oncology, 2016. 27, DOI: 10.1093/annonc/mdw390.2. | Abstract |
| Ueno, M.; Sugimori, K.; Taguri, M.; Ohkawa, S.; Kobayashi, S.; Miwa, H.; Kaneko, T.; Morimoto, M.; Yamanaka, T. Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer. Nutr. Cancer 2022, 74, 122–130 | Geen uitkomsten uit PICO |
| Ulutin, H.C., F. Arpaci, and Y. Pak, Megestrol acetate for cachexia and anorexia in advanced non-small cell lung cancer: a randomized study comparing two different doses. Tumori, 2002. 88(4): p. 277-80. | Vergelijking van dosissen |
| van der Meij BS, Langius JA, Smit EF, et al. Oral nutritional supplements containing (n-3) polyunsaturated fatty acid affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr. 2010;140:1774-1780 | Geen palliatieve patiënten |
| van der Meij BS, Langius JA, Spreeuwenberg MD, et al. Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. Eur J Clin Nutr. 2012;66:399-404 | Geen palliatieve patiënten |
| Vayne-Bossert, P., et al., Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochrane Database of Systematic Reviews, 2017. 7: p. CD012002. | Foute populatie |
| Velema, M.S., B.H. Kwa, and W. de Ronde, Should androgenic anabolic steroids be considered in the treatment regime of selected chronic obstructive pulmonary disease patients? Current Opinion in Pulmonary Medicine, 2012. 18(2): p. 118-24. | Narrative review |
| Villa EF, Ferretti I, Grottola A, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001; 84: 881-885 | Bedoeld als antineoplastische behandeling |
| Villarino-Sanz, M., et al. Study of nutritional and inflammatory status of a powdered, eicosapentaenoic fatty acid enriched nutritional supplement versus a standard liquid supplement in cancer patients. Clinical nutrition, supplement, 2011. 6, 145. | Abstract |
| von Haehling, S., et al., Cardiac cachexia: a systematic overview. Pharmacology & Therapeutics, 2009. 121(3): p. 227-52. | Narrative review |
| Von, H.S. Novel treatment approaches to cancer cachexia: results from two recent randomized controlled trials using essential amino acids and espidolol. Journal of cachexia, sarcopenia and muscle, 2017. 8, 151 DOI: 10.1002/jcsm.12182. | Abstract |
| Wan, G.Y., et al., Effects of enteral nutritional rich in n-3 polyunsaturated fatty acids on the nutritional status of gastrointestinal cancer patients: a systematic review and meta-analysis. European Journal of Clinical Nutrition, 2020. 74(2): p. 220-230. | Geen full-text |
| Waqar, S. Megestrol acetate with or without mirtazapine in treating cancer patients with weight loss or loss of appetite. Clinicaltrials.gov, 2011. | Geen full-text |
| Weisberg, J., et al. Megestrol acetate induces weight gain and stimulates ventilation in underweight COPD patients: a randomized, double-blind, placebo-controlled, multi-centre trial. American journal of respiratory and critical care medicine, 2001. 163, A503. | Abstract |
| Weisberg, J., et al., Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest, 2002. 121(4): p. 1070-8. | Stable COPD |

| Referentie | Reden voor exclusie |
|---|---|
| Werner, K., et al., Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial. <i>Lipids in Health & Disease</i> , 2017. 16(1): p. 104. | Foute vergelijking |
| Whiting, P.F., et al., Cannabinoids for medical use: A systematic review and meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015. 313(24): p. 2456-2473. | Geen indicaties uit PICO |
| Wiedenmann, B., et al., A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. <i>Journal of Supportive Oncology</i> , 2008. 6(1): p. 18-25. | Geen full-text |
| Wigmore SJ, Barber MD, Ross JA, Tisdale MJ & Fearon KC (2000) Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. <i>Nutrition & Cancer</i> 36(2), 177–184 | Geen RCT |
| Wigmore, S., et al. Ibuprofen versus placebo in the treatment of pancreatic cancer cachexia(abstract). <i>Gut</i> , 1995. 36, A479-80. | Abstract |
| Willemse, P.H., et al., A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. <i>European Journal of Cancer</i> , 1990. 26(3): p. 337-43. | Gaat over antitumorale effecten |
| Willox JC, Corr J, Shaw J, et al: Prednisolone as an appetite stimulant in patients with cancer. <i>Br Med J (Clin Res Ed)</i> 288:27, 1984 | Onduidelijk hoeveel palliatieve patiënten |
| Yeh, K.Y., et al., Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013. 116(1): p. 41-8. | Minderheid palliatieve patiënten |
| Yeh, S.S., S. Lovitt, and M.W. Schuster, Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly. <i>Journal of Nutrition, Health and Aging</i> , 2009. 13(5): p. 448-454. | Foute populatie |
| Yennurajalingam, S., et al. Dexamethasone and symptom distress: results of a placebocontrolled, double-blind randomized controlled trial in patients with advanced cancer. <i>Supportive care in cancer</i> , 2012. 20, S234 DOI: 10.1007/s00520-012-1479-7. | Abstract |
| Yennurajalingam, S., et al., The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: Results of a double-blind placebo-controlled randomized study. <i>Journal of Palliative Medicine</i> , 2012. 15(10): p. 1059-1064. | Onduidelijk hoeveel palliatieve patiënten |
| Yu, J., et al., Effect of preoperative immunonutrition on postoperative short-term clinical outcomes in patients with gastric cancer cachexia: a prospective randomized controlled trial. <i>World Journal of Surgical Oncology</i> , 2024. 22(1). | Chirurgisch behandelde patiënten |
| Yu, K., et al., Immunonutrition vs Standard Nutrition for Cancer Patients: A Systematic Review and Meta-Analysis (Part 1). <i>Jpen: Journal of Parenteral & Enteral Nutrition</i> , 2020. 44(5): p. 742-767. | Geen relevante interventie |
| Yule, M.S., et al., Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2024. 15(3): p. 853-867. | Foute uitkomsten |
| Zecca, E. Efficacy of megestrol acetate on anorexia in patients with advanced non hormone-related tumors: a double-blind placebo controlled clinical trial. <i>European journal of cancer</i> , 1995. 31a, S261. | Abstract |

Tabel 18. Overzicht van studies die buiten beschouwing gelaten worden o.b.v. bijsturing van de onderzoeksvraag

| Referentie | Medicatie | Aandoening | Studiotype |
|---|-----------|------------|------------|
| Agteresch HJ, Dagnelie PC, van der Gaast A, et al. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. <i>J Natl Cancer Inst</i> 2000;92:321-8 | ATP | Kanker | RCT |

| Referentie | Medicatie | Aandoening | Studietype |
|--|-----------------|------------|------------|
| Broekhuizen, R., et al., Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. <i>Thorax</i> , 2005. 60(5): p. 376-82. | Omega-3 FA | COPD | RCT |
| Chlebowski, R.T., et al., Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. <i>Cancer</i> , 1987. 59(3): p. 406-10. | Hydrazine | Kanker | RCT |
| Chlebowski, R.T., et al., Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 1990. 8(1): p. 9-15. | Hydrazine | Kanker | RCT |
| Chlebowski, R.T., et al., Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. <i>Cancer</i> , 1986. 58(1): p. 183-6. | Nandrolone | Kanker | RCT |
| Cummins, M.J. and B. Pruitt, Low-dose oral use of human interferon-alpha in cancer patients. <i>Journal of Interferon & Cytokine Research</i> , 1999. 19(8): p. 937-41. | INF | Kanker | RCT |
| Daneryd, P., et al., Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. <i>Cancer Research</i> , 1998. 58(23): p. 5374-9. | Erythropoietine | Kanker | RCT |
| Del Fabbro, E., et al., Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. <i>Journal of Clinical Oncology</i> , 2013. 31(10): p. 1271-6. | Melatonine | Kanker | RCT |
| Gordon, J.N., et al., Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. <i>Gut</i> , 2005. 54(4): p. 540-5. | Thalidomide | Kanker | RCT |
| Groarke, J.D., et al., Ponesegromab for the Treatment of Cancer Cachexia. <i>New England Journal of Medicine</i> , 2024. 391(24): p. 2291-2303. | Ponesegromab | Kanker | RCT |
| Harrison, M.E., et al., Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review. <i>Appetite</i> , 2019. 137: p. 62-72. | Cyproheptadine | Mix | SR |
| Jatoi, A., et al., A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. <i>Cancer</i> , 2007. 110(6): p. 1396-403. | Etanercept | Kanker | RCT |
| Jatoi, A., et al., A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). <i>Lung Cancer</i> , 2010. 68(2): p. 234-9. | Infliximab | Kanker | RCT |
| Kosty MP, Fleishman SB, Herndon II JE, et al: Cisplatin, vinblastine, and hydrazine sulfate in advanced non-small lung cancer: A randomized placebo-controlled, double blind phase III study of the Cancer and Leukemia Group B. <i>J Clin Oncol</i> 12:1113-1120, 1994 | Hydrazine | Kanker | RCT |
| Kraft, M.; Kraft, K.; Gärtner, S.; Mayerle, J.; Simone, G.; Weber, E.; Schütte, K.; Stieler, J.; Koula-Jenik, H.; Holzhauser, P.; et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)—A randomized multicentre trial. <i>Nutr. J.</i> 2012, 11, 52 | L-carnitine | Kanker | RCT |
| Lindholm, E., et al., Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients. <i>Clinical Cancer Research</i> , 2004. 10(20): p. 6855-64. | Erythropoietine | Kanker | RCT |
| Lissoni P, Chilelli M, Villa S, et al: Five years survival in metastatic nonsmall cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. <i>J Pineal Res</i> 35:12-15, 2003 | Melatonine | Kanker | RCT |
| Lissoni, P., et al., Is there a role for melatonin in the treatment of neoplastic cachexia? <i>European Journal of Cancer</i> , 1996. 32A(8): p. 1340-3. | Melatonine | Kanker | RCT |
| Loprinzi CL, Goldberg RM, Su JQ, et al: Placebo controlled trial of hydralazine sulfate in patients with newly diagnosed NSCLC. <i>J Clin Oncol</i> 12:1126-1129, 1994 | Hydrazine | Kanker | RCT |

| Referentie | Medicatie | Aandoening | Studietype |
|---|---------------------------------|------------|------------|
| Loprinzi CL, Kuross SA, O'Fallon JR, et al: Randomized placebo controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 12:1121-1125, 1994 | Hydrazine | Kanker | RCT |
| Lundholm, K., et al., Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clinical Cancer Research, 2007. 13(9): p. 2699-706. | Insuline | Kanker | RCT |
| Mehra, M.R., et al., Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. Journal of Heart & Lung Transplantation, 2006. 25(7): p. 834-8. | Visolie | Hartfalen | RCT |
| Mehrzad, V., R. Afshar, and M. Akbari Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trial. Advanced biomedical research, 2016. 5, 60 DOI: 10.4103/2277-9175.179182. | Pentoxifylline | Kanker | RCT |
| Miki, K., et al., Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial. PLoS ONE [Electronic Resource], 2012. 7(5): p. e35708. | Ghrelin | COPD | RCT |
| Persson, C., et al., Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition, 2005. 21(2): p. 170-8. | Visolie vs. melatonine | Kanker | RCT |
| Reid, J., et al., Thalidomide for managing cancer cachexia. Cochrane Database of Systematic Reviews, 2012(4): p. CD008664. | Thalidomide | Kanker | SR |
| Sharma, S., et al., Anabolic steroids in COPD: a review and preliminary results of a randomized trial. Chronic Respiratory Disease, 2008. 5(3): p. 169-76. | Nandrolone | COPD | RCT |
| Stewart Coats, A.J., et al., Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). Journal of Cachexia, Sarcopenia and Muscle, 2016: p. 355-365. | Espindolol | Kanker | RCT |
| Wen, H.S., et al., Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy, 2012. 58(6): p. 461-7. | Megestrol acetate + Thalidomide | Kanker | RCT |
| Wilkes EA, Selby AL, Cole AT, Freeman JG, Rennie MJ, Khan ZH. Poor tolerability of thalidomide in end-stage oesophageal cancer. European Journal of Cancer Care 2011;DOI: 10.1111/j.1365-2354.2011.01255.x. [Epub ahead of print]:1-8. | Thalidomide | Kanker | RCT |